



Review article

Potential applications of mesenchymal stem cells in ocular surface immune-mediated disorders

Pier Luigi Surico^{a,b,c}, Vincenzo Barone^{b,c}, Rohan Bir Singh^a, Marco Coassin^{b,c}, Tomas Blanco^a, Thomas H. Dohlman^a, Sayan Basu^d, Sunil K. Chauhan^a, Reza Dana^a, Antonio Di Zazzo^{b,c,*}

^a Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA

^b Department of Ophthalmology, Campus Bio-Medico University Hospital, Rome 00128, Italy

^c Cornea Rare Diseases Center, Fondazione Policlinico Campus Bio-Medico, Rome 00128, Italy

^d Brien Holden Eye Research Centre (BHERC), L. V. Prasad Eye Institute, Hyderabad, Telangana, India

ARTICLE INFO

Keywords:

Stem cells

Mesenchymal stem cell

Ocular surface

Corneal immunity

ABSTRACT

We explore the interaction between corneal immunity and mesenchymal stem/stromal cells (MSCs) and their potential in treating corneal and ocular surface disorders. We outline the cornea's immune privilege mechanisms and the immunomodulatory substances involved. In this realm, MSCs are characterized by their immunomodulatory properties and regenerative potential, making them promising for therapeutic application. Therefore, we focus on the role of MSCs in immune-mediated corneal diseases such as dry eye disease, corneal transplantation rejection, limbal stem cell deficiency, and ocular graft-versus-host disease. Preclinical and clinical studies demonstrate MSCs' efficacy in promoting corneal healing and reducing inflammation in these conditions. Overall, we emphasize the potential of MSCs as innovative therapies in ophthalmology, offering promising solutions for managing various ocular surface pathologies.

1. Introduction

The cornea, as the outermost layer of the eye, is not only a transparent optical element, but also a vital immunological interface. The intricate network of immune cells within the cornea orchestrates a delicate balance between safeguarding against pathogens and maintaining immune tolerance. Recent studies have unveiled a compelling interplay between corneal immunity and mesenchymal stem/stromal cells (MSCs), highlighting their potential collaborative roles in maintaining ocular surface homeostasis. Herein, we explore the molecular and cellular mechanisms that underlie the interaction between corneal immunity and MSCs, exploring the potential implications and future applications for ocular immune modulation and regenerative medicine. Moreover, we review current evidence regarding the mechanisms by which MSCs contribute to corneal immune regulation in the context of numerous immune-mediated corneal disorders.

2. Corneal immunity: A brief overview

The ocular surface is referred to as immune-privileged because,

despite its ability to build a strong immunological defense, it also employs tight immune surveillance systems to prevent undesirable local inflammatory reactions and preserve corneal transparency and visual function²⁹. The underlying corneal immune privilege is maintained by various factors, including the morphological and structural properties of the corneal tissue. Key structural components such as the intact epithelial barrier, the absence of blood and lymphatic vessels in the central cornea, and the presence of tight junctions between corneal epithelial cells help to limit the entry and movement of immune cells and pathogens. Additionally, the corneal stroma's organized collagen matrix and the presence of a basement membrane support corneal transparency and integrity, which are crucial for immune privilege¹²⁵. These structural features—along with soluble immunomodulatory molecules, resident immune cells, peripheral tolerance to ocular antigens, and neuroimmune cross-talk—collectively contribute to the maintenance of corneal immune privilege.

²⁹. The ocular surface and aqueous humor contribute to the cornea's immunological privileged status by preventing the penetration of pathogenic microorganisms, allergens, and toxins. This process is dependent on tear fluid, the glycocalyx that covers the surface of apical

* Corresponding author at: Department of Ophthalmology, Campus Bio-Medico University Hospital, Rome 00128, Italy.

E-mail address: a.dizazzo@policlinicocampus.it (A. Di Zazzo).

<https://doi.org/10.1016/j.survophthal.2024.07.008>

Received 17 May 2024; Received in revised form 29 July 2024; Accepted 29 July 2024

Available online 7 August 2024

0039-6257/© 2024 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

cells, intercellular adhesion structures, and the basement membrane of the epithelium^{12,98}.

Cornea avascularity is a critical anatomical property that ensures immunological privilege. In fact, the lack of afferent vessels prevents infiltration of immune cells to the cornea^{142,209}. This privilege of the corneal tissue derives from an interplay between factors that impede neoangiogenesis, such as corneal stem cell functionality^{54,70}, epithelial basement membrane-derived anti-angiogenic factors (endostatin, neostatins, restin, arresten, canstatin, tumstatin)^{1,53}, corneal soluble anti-angiogenic factors (sflt-1⁴, angiostatin⁷⁰, INF- γ ^{105,210}, FasL¹⁴⁹, PD-L1⁹⁴), and neurogenic factors^{42,58}.

Several immunomodulatory substances play a crucial role in maintaining corneal homeostasis and are constitutively produced by the corneal epithelium^{9,29}. For example, PD-L1 induces T cell apoptosis, thereby reducing activated T cell effector responses^{51,61,165}. PEDF effectively inhibits the maturation and activation of corneal resident leukocytes^{96,171,172}. TSP-1 activates TGF β -1, which promotes the immunosuppressive phenotype of regulatory T cells (Treg) and inhibits proinflammatory immune responses^{156,196}. Galectin-9 suppresses the CD8 + cell response and enhances Treg function^{161,162}. These substances collectively contribute to the intricate immunoregulatory environment of the cornea, crucial for maintaining ocular health and immune balance.

Corneal immunological regulation is also dependent on antigen-presenting cells (APCs), which include stromal CD11b+CD11c- macrophages/monocytes, anterior stromal CD11b+CD11c+ dendritic cells (DCs), and epithelial Langerhans cells^{74,76,78,102,161,205}. These cells tend to form a negative gradient from the periphery and limbal regions, where they are more concentrated, to the center of the cornea⁷⁶. Under steady-state conditions, it appears that corneal APCs in the peripheral cornea are MHC class II-positive, but in the central cornea they are regularly MHC class II-negative with a low expression of CD80, CD86, CD40, which represent co-stimulatory factors^{75,76}. These latter cells have decreased antigen presentation capability, increased synthesis of regulatory cytokines, and a proclivity for Treg formation and proliferation; for this reason, they are referred to as tolerogenic APC^{56,131}. Nevertheless, inflammation can activate and mobilize APC, which migrate through efferent lymphatic vessel and then activate naïve T cell by secreting T cell-polarizing cytokines and antigenic and co-stimulatory signals, resulting in differentiation into effector Th1, Th2, or Th17 cells^{19,28,50,69,103,179} in the draining lymph nodes.

A critical immunoregulatory process that limits and inhibits the proinflammatory effector T-cell response is dependent on Tregs, which are commonly defined as CD4 + , CD25 + and Foxp3 + cells^{60,154}. Tregs maintain self-antigen tolerance, avoiding autoimmunity, and preventing excessive inflammatory responses^{139,213}. They regulate immune homeostasis through several processes, including cytotoxicity, release of soluble substances, metabolic competition, and suppression of antigen presentation¹⁹⁴. Moreover, Tregs play a crucial role in promoting corneal graft survival by suppressing immune responses and preventing graft rejection, highlighting the potential of therapies that enhance graft success through the induction and support of Treg function^{6,87}. Subconjunctival injection of Treg cells has been shown to significantly decrease the frequencies of mature antigen-presenting cells in the graft and draining lymph nodes (DLNs), suppress Th1 frequencies in DLNs, and inhibit CD45 + cell infiltration into the graft. Additionally, locally delivered Treg cells significantly reduced the expression of IFN- γ , increased levels of IL-10 and TGF- β in the graft, and promoted long-term allograft survival¹⁶³.

Neuro-immune interactions are crucial in preserving corneal immune privilege. Trigeminal nerve's ophthalmic branch extensively innervates the cornea, with neuropeptide-mediated interactions between the neurological and immune systems being essential for ocular surface homeostasis¹⁵¹. Neuropeptides modulate immune responses and affect vascular cells, with bidirectional production by immune cells and neurons^{22,30,159,176}. Substance P (SP) enhances wound healing, stimulates

immune cells, and induces dendritic cell maturation^{11,106,135,137}. Calcitonin gene-related peptide (CGRP) reduces proinflammatory cytokines and modulates immune cell costimulatory molecules^{26,82}. Vasoactive intestinal peptide (VIP) inhibits macrophage and dendritic cell activity, affects T cell differentiation, and promotes regulatory dendritic cells^{43,44,95}. α -melanocyte stimulating hormone (α -MSH) reduces inflammation and cytokine release and promotes regulatory T cell development^{10,148,199}.

As outlined above, immune privilege is critical to the immunological homeostasis of the eye, and this delicate balance between avoiding excessive inflammation while still protecting the eye from external insults is altered in various disorders pertaining the ocular surface. In this setting, MSCs emerge as a promising and innovative immunomodulatory and regenerative therapeutic strategy for a wide spectrum of corneal and ocular surface pathologies. This necessitates a more comprehensive examination of their functions across various clinical subsets¹⁵³.

3. Mesenchymal stem cells

The terminology “stromal” or “stem” attributed to mesenchymal cells has been used variably in the scientific literature, leading to confusion; however, some researchers argue for a distinction between the two terms^{83,136,195}. The terminology “mesenchymal stromal cells” was initially proposed to reflect the heterogeneity and functional properties of the cells isolated from various tissues. MSCs were considered to possess immunomodulatory and tissue-repair properties without necessarily having the full differentiation potential typically associated with stem cells¹⁹⁵. They were thought to play a supportive role in tissue repair by secreting various growth factors and cytokines. Mesenchymal stem cells were considered as multipotent cell capable of differentiating in different mesoderm-derived cell types⁴⁷. They were characterized by self-renewal capacity and ability to transform into several cell types in a context-dependent fashion. Specifically, MSCs can differentiate into osteoblasts in the presence of osteogenic stimuli, adipocytes under adipogenic conditions, and chondrocytes when exposed to chondrogenic environments. Additionally, under specific signals, MSCs can give rise to myocytes, neurons, and endothelial cells, demonstrating their versatile potential for tissue regeneration and repair across various physiological and pathological contexts;¹⁴⁵ however, recent research has suggested that the distinction between the two terms may not be clear-cut. In summary, while mesenchymal stromal and stem cell have been used equally, there is ongoing debate within the scientific community regarding their precise definitions and distinctions. The Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy established specific criteria for MSCs identification⁴⁸. These are characterized by their ability to adhere to surfaces made of plastic, to develop clones, to express of specific markers such as CD73, CD90 and CD105, and the absence of hematopoietic and endothelial markers CD45, CD34, CD14, CD11b, CD79 α , CD19, HLA-DR⁴⁸. Moreover, MSCs must demonstrate the potential for in vitro differentiation into mesodermal cell lineages^{35,191}. MSCs can differentiate in cell of adipose, cartilage, and bone tissues¹⁴⁶. Moreover, human and murine specific type of MSC cells can mature in neuroectodermal or endodermal cells, such as neurons, endothelial cells, and hepatocytes^{33,93,122,183}.

MSCs are known for their ability to preserve their potent functions, such as self-renewal and multi-lineage differentiation, across different steps of their maturation^{104,123}. This includes their transition from early progenitors to intermediate stages like preosteoblasts, preadipocytes, and prechondrocytes, ultimately leading to fully differentiated osteoblasts, adipocytes, and chondrocytes. Throughout these stages, MSCs maintain their capacity to respond to specific signals and differentiate into various cell types, demonstrating their versatility and regenerative potential. Therefore, these cells are considered for their important plasticity features, which make them a promising target of study for tissue repairing and regeneration^{23,71,186}. Importantly, these cells have been found in a variety of tissues in the human body, including bone

marrow, adipose tissue, amniotic fluid, placenta, and umbilical cord ^{17, 47,84,111,188,201}.

Autologous adult stem cells have been extensively applied in studies owing to their immunocompatibility, with minimal ethical concerns ²¹⁵. This is an advantage for their application, in contrast with cells derived from neonatal tissues (embryo, cord or placenta) and induced pluripotent stem cells, which have limited use in humans ⁶⁸. These limitations include complexity of cellular regulation, promotion of tumor growth, immunogenicity, genetic manipulation, ethical concerns, and difficulties in their preservation ^{18,187}.

Notably, MSCs exhibit a strong tropism towards sites of inflammation or injured tissues, even when administered systemically ^{86,115,133, 169}. This characteristic is essential for their tissue repair function and contribution to immune homeostasis, which refers to the delicate and finely regulated balance of appropriate immune activation and suppression in tissues and organs, maintained by a complex interplay of various cellular components and chemical factors. MSCs potent immunomodulatory capabilities, mediated by the release of an array of immunoregulatory factors, suppress both the adaptive and innate response ^{31,86,127,200}. MSCs exhibit extensive immunomodulatory capabilities through both direct cell-cell interactions and the secretion of soluble factors. These cells play a pivotal role in modulating the immune response by inhibiting T cell proliferation and functionality, attenuating NK cell activation, and suppressing the differentiation and activation of APCs ¹⁵³. Furthermore, MSCs impede B cell proliferation and differentiation into plasma cells, diminish the antigen-presenting capacity of macrophages, and reduce neutrophil apoptosis, infiltration, and effector functions ^{62,85}. Additionally, MSCs induce the differentiation of Tregs, thereby contributing to immune tolerance. (Fig. 1) These comprehensive immunomodulatory properties underscore the therapeutic potential of

MSCs in various immune-mediated disorders, as discussed in details in the following Section III.A.

Interestingly, MSCs have been proven to release several factors in their culture media ⁵². This so-called "secretome" includes chemokines, cytokines, growth factors, and immunomodulatory proteins. Additionally, MSCs secrete microvesicles and exosomes, which act as packaging systems to deliver these bioactive molecules to target cells, enhancing the therapeutic potential of the secretome ⁷⁷. The application of this secretome has been studied in wound healing, cardiac infarction, hepatic diseases, brain ischemia, inflammatory disorders, and ophthalmic diseases ^{21,67,77,114,120,132,182,202,212}. Given the multipotentiality of MSCs, we here discuss the potential application of MSCs in regulating immune-mediated processes underlining principal corneal disorders in which ocular surface immune homeostasis is disrupted (Fig. 2).

Additionally, recent studies have identified a resident population of MSCs within the cornea ^{63,157}. These corneal MSCs exhibit unique properties that contribute to corneal homeostasis and repair ¹⁶. Notably, corneal MSCs have demonstrated considerable anti-inflammatory and anti-scarring effects. These cells secrete anti-inflammatory cytokines and modulate immune cell activity, reducing inflammation in various corneal disease models ^{90,168}. Furthermore, corneal MSCs have shown efficacy in minimizing fibrosis and promoting tissue repair, thereby reducing scarring and enhancing corneal clarity ^{16,158}. Although most current research on corneal MSCs is not directly related to the specific disease entities we focus on, their potential to mitigate inflammation and fibrosis underscores their importance as a therapeutic option ¹⁵⁸. By including these findings, we present a more comprehensive perspective on potential treatments for corneal diseases (Table 1).




Fig. 1. Sources, secreted factors, and immunomodulatory effects of Mesenchymal Stem Cells (MSCs) on various immune cell populations. Interleukin-6 (IL-6), Hepatocyte Growth Factor (HGF), Prostaglandin E2 (PGE2), Transforming Growth Factor Beta (TGF-β), Programmed Death Ligand 1 (PD-L1), Indoleamine 2,3-dioxygenase (IDO), Tumor Necrosis Factor-α-stimulated Gene 6 (TSG-6), Interleukin-10 (IL-10), Tumor Necrosis Factor Alpha (TNF-α), Matrix Metalloproteinase-9 (MMP-9), and Soluble Human Leukocyte Antigen-G isoform 5 (sHLA-G5).




Fig. 2. Immunomodulatory effects and outcomes of Mesenchymal Stem Cells (MSCs) application in immune-mediated ocular surface disorders. Dry eye disease manifests as chronic inflammation of the ocular surface, characterized by tear film instability and ocular discomfort. Corneal transplantation highlights the challenges of immune rejection despite advancements in surgical techniques, where MSCs offer potential as adjunctive therapy to enhance graft survival. Limbal stem cell deficiency underscores the critical need for regenerative strategies to restore corneal epithelial integrity and vision. Ocular Graft-versus-Host Disease illustrates the systemic immune dysregulation affecting the ocular surface post allogeneic hematopoietic stem cell transplantation, where MSCs demonstrate immunomodulatory properties to mitigate inflammation and improve clinical outcomes. Dendritic Cells (DC), T helper 17 cells (Th17), Graft-versus-Host Disease (GVHD).

3.1. Immune-mediated corneal diseases and application of mesenchymal stem cells

3.1.1. Dry eye disease

Dry eye disease (DED) is a high-prevalence ocular surface disorder characterized by disruption of quantitative and qualitative tear film characteristics, inflammation, and nerve alterations^{37,38}. DED is an autoimmune process that may be part of the Sjögren's syndrome or overlap with other systemic autoimmune conditions. Although the pathophysiology of DED is still not entirely clear, it has been proven that inflammation and the failure of ocular surface immune homeostasis plays a crucial role in disease progression¹⁷⁸. Protecting and preserving ocular surface homeostasis requires strict regulation of both innate and adaptive immunity in the ocular surface environment¹³⁰. Therefore, DED may result from a disruption of this immunological homeostasis^{13,73,144,177}.

Given the regenerative and antiinflammatory potential of MSCs, the therapeutic application of these cells in DED has been explored. Investigators demonstrated that treatment with extracellular vesicle derived from MSCs human umbilical cord (hUC-MSC-sEVs) in a dessicating dry eye murine model proved to be beneficial in maintaining corneal health, by increasing tear production, enhancing goblet cells density, inhibiting apoptosis and reducing CD4 + T cell migration, and reducing proinflammatory cytokines in tear fluid¹⁹⁸. In a rabbit dry eye model, injection of hUC-MSC-sEVs induced macrophages to adopt antiinflammatory function (M2) and promoted Tregs expansion. This dual effect contributed to reduced inflammation and improved tissue damage¹¹². Furthermore, in a murine model DED using benzalkonium chloride, topical application of exosomes of MSCs derived from murine adipose tissue demonstrated anti-inflammatory properties by inhibiting cell apoptosis, reducing proinflammatory cytokine levels such as interleukin-1 β , interleukin -6, interleukin -1 α , interferon gamma and tumor necrosis factor alpha, and increasing the expression of interleukin-10, an anti-inflammatory cytokine¹⁹⁷. Moreover, MSC-EVs have been showed

to play a potential role in alleviating the neuropathic physiopathology of DED⁵. In a murine pre-clinical study on Sjögren syndrome, olfactory ecto-MSCs-derived exosomes effectively slowed down the disease progression and suppressed Th cell responses by expressing high levels of PD-L1¹⁵⁰. In a similar model, injection of MSCs extract effectively preserve salivary and lacrimal glands function, upregulating the expression of various beneficial genes including IL-10a and simultaneously reducing the levels of TGF- β 1, MMP2, CASP3, IL-1 β and TNF- α .

In a mouse model of DED, topical treatment with extracellular vesicles derived from MSCs reduced disease severity. This treatment also decreased the expression of TNF- α , IL-6, and IL-1 β , lowered the frequency of Th17 cells, and inhibited the maturation of DCs⁷². Interestingly, the adoptive transfer of MSCs derived from human umbilical cords improved symptoms and mitigated pathological alterations in the submandibular glands of mice by regulating Tim-3 expression, which was decreased in the cohort of patients with SS. This led to reduced local inflammation, fibrosis, and epithelial-mesenchymal transition (EMT)¹⁸⁵. Another study investigating the application of MSCs derived from human umbilical cords in a rabbit model of autoimmune dacryoadenitis found that systemic infusion of these cells effectively reduced chronic inflammation in the lacrimal glands and improved clinical symptoms. Furthermore, the treated animals exhibited significantly lower levels of M1 macrophage activation markers, while their M2 anti-inflammatory phenotype was promoted¹¹⁸.

In aqueous-insufficient dry eye induced in mice, eGFP-expressing MSC adoptive transfer yielded significant improvements in lacrimal gland (LG) regeneration, modulating the immune response by delaying macrophage infiltration and decreasing TNF α expression, coupled with heightened levels of interleukin-6, and a significant increased regenerative capacity compared to the control groups⁴⁶. Intraperitoneal injection of MSCs derived from murine bone marrow in Sjögren syndrome model of dry eye increased tear production and decreased the size of lymphocytic foci in the LGs³. In another study, periorbital administration of human bone marrow derived-MSCs led to a reduction of effector

Table 1

Summary of studies on the application of mesenchymal stem cells (MSCs) in corneal and ocular surface immune-mediated diseases.

Authors	Year of publication	Type of mscs	Type of study	Outcomes
Wang et al. ¹⁹⁹	2023	hUC-MSC-EVs	Mouse model of desiccation-induced DED	hUCMSCs-EVs alleviate DED signs, suppress inflammation, and restore homeostasis of the corneal surface.
Na Li et al. ¹¹³	2022	hUC-MSC-sEVs	Rabbit dry eye model	hUC-MSC-sEVs alleviated autoimmune dacryoadenitis by promoting M2 macrophage polarization and Treg generation.
Ke Rui et al. ¹⁵¹	2022	Olfactory ecto-MSC-Exos	ESS mouse model	OE-MSC-Exos markedly attenuated disease progression and reduced Tfh cell response.
Wang et al. ¹⁹⁸	2021	ADSC-Exos	BAC-induced mouse dry eye model	ADSC-Exos alleviate ocular surface inflammation.
Abughanam et al. ²	2019	BM-MSCsE	SS-like disease mouse model	MSCsE preserved the function of salivary and lacrimal glands, upregulated the expression of various beneficial genes, downregulated the expression of proinflammatory genes, promoted peripheral tolerance and inhibited B cell activity.
Guo et al. ⁷³	2022	hUC-MSC-EVs	Mouse dry eye model	MSC-EVs reduced severity of DED, downregulated the expression of inflammatory cytokines, the frequency of Th17 cells and inhibited the increase in the number and maturation of DCs.
Sun et al. ¹⁸⁶	2022	hUC-MSCs	ESS mouse model	hUC-MSCs ameliorate SS-like symptoms and pathological changes in the submandibular glands.
Lu et al. ¹¹⁹	2020	hUC-MSCs	Rabbit model of SS dry eye	Systemic infusion of hUC-MSCs after disease onset efficiently diminished the chronic inflammation in diseased LGs and improved the clinical symptoms.
Dietrich et al. ⁴⁷	2019	eGFP-MSC	Aqueous-deficient dry eye mouse model	eGFP-MSC transplantation yielded significant improvements in LG regeneration, delaying macrophage infiltration and decreasing TNF α expression, coupled with an increase in IL–6 expression.
Aluri et al. ⁴	2017	BM-MSCs	Mouse model of SS dry eye	Treatment with BD-MSCs increases tear production.
Lee et al. ¹⁰⁹	2015	human BD-MSCs	Murine model of an inflammation-mediated dry eye	Periorbital administration of BD-MSCs led to a reduction in CD4(+) T cell infiltration and decreased levels of inflammatory cytokines in the intraorbital gland and ocular surface.
Jia et al. ⁹³	2022	BM-MSC-exos	Corneal allograft rejection rat model	Subconjunctival injection of MSC-exos significantly prolonged graft survival time and inhibited the infiltration of CD4 + and CD25 + T cells.
Lu et al. ¹¹⁸	2019	BM-MSCs	Rat model of corneal allograft rejection	Subconjunctival injection of MSCs was effective in prolonging corneal allograft survival.
Jia et al. ⁹²	2018	BM-MSCs	Rat model of corneal allograft rejection	Subconjunctival injections of BM-MSCs promoted corneal allograft survival, reduced CD4 + and CD68 + cell infiltration, and enriched Treg population in the allografts.
Lohan et al. ¹¹⁷	2018	third-party allogeneic MSC	Pre-existing anti-donor immunity corneal transplantation rat model	Allo-MSC extended rejection-free graft survival and significantly increased proportions of CD4 + FoxP3 + regulatory T cells in the graft DLNs.
Lee et al. ⁸⁰	2014	human MSCs	Mouse allogeneic corneal transplantation model	IV human MSCs reduced the activation and migration of CCR7(+) APCs in the cornea and DLNs in allogeneic corneal transplantation.
Omoto et al. ¹⁴¹	2014	BM-MSCs	Murine model of corneal transplantation	Systemically administered BM-MSCs specifically home to the inflamed ocular surface and promote allograft survival by inhibiting APC maturation and induction of alloreactive T cells.
O Treacy et al. ¹⁹⁰	2014	BM-MSCs	Allogeneic rat cornea transplantation model	Allo- and third-party BM-MSCs treatment prolongs corneal allograft survival by suppressing peripheral immune responses and promoting an intragraft immunoregulatory milieu.
Oh et al. ¹³⁹	2012	Human MSCs	Mouse model of corneal allotransplantation	Human MSCs improve the survival of corneal allografts without engraftment and primarily by secreting TSG–6.
Soleimani et al. ¹⁷⁶	2023	Human BM-MSCs	Mouse corneal epithelial and limbal injury model	injection of hBM-MSC using both intrastromal and subconjunctival methods improve wound healing and reduce neovascularization and opacity.
P é rez et al. ¹⁴⁴	2023	BM-MSCs and limbal epithelial cells	Phase I–II clinical trial.	BM-MSCs transplantation improves the central corneal epithelial phenotype despite only minor changes in the anatomical structures of the limbus.
Gao et al. ⁶⁷	2023	Pax6-reprogrammed BM-MSCs	Mouse models of chemical corneal burn.	Pax6-reprogrammed BM-MSCs attached to and replenished the damaged cornea through the formation of stratified corneal epithelium.
Khorolskay et al. ¹⁰²	2023	L-MSCs-EGFP	Rabbits with a modeled LSCD.	L-MSCs-EGFP transplantation led to reduction of limbal vascularization, neoangiogenesis, epithelialization, and inflammatory infiltration.
Calonge et al. ²⁵	2019	Allogeneic BM-MSCs transplantation	Randomized, double-masked pilot trial in human.	BM-MSCs transplantation was as safe and effective as CLET.
Li et al. ¹¹¹	2018	BM-MSC	Alkali burns rabbit model.	BM-MSCs transplantation group experienced a significant reduction in the severity of LSCD.
Yun et al. ²⁰⁹	2017	iPSC-MSCs and BM-MSCs	Murine model of corneal injury induced by chemicals and mechanical trauma.	mice treated with iPSC-MSCs or BM-MSCs demonstrated reduction in corneal opacity, inflammatory infiltration, pro-inflammatory cytokines
Galindo et al. ⁶⁶	2017	hAT-MSCs	Rabbits models of LSCD	hAT-MSCs reduced inflammation and restrained the progression of corneal neovascularization and opacity.
Mittal et al. ¹³⁰	2016	BM-MSCs	In vivo mouse model of ocular injury	MSCs have the capacity to restore corneal transparency by secreting high levels of hepatocyte growth factor (HGF).
Ke et al. ¹⁰⁰	2015	BM-MSCs	Alkali burns rat model	Polysaccharide and MSCs are safe and effective treatments for corneal alkali burns and that their benefits are additive when used in combination.
Holan et al. ⁸²	2015	BM-MSCs	Alkali-injured rabbit model	BM-MSCs' therapeutic effect on healing of injured corneal surface is comparable to that of tissue-specific LSCs.
Cejkova et al. ²⁸	2013	BM-MSCs	Alkali burns rabbit model	BM-MSCs growing on nanofiber scaffolds and transferred effectively suppressed corneal inflammation as well as neovascularization and significantly accelerated corneal healing.

(continued on next page)

Table 1 (continued)

Authors	Year of publication	Type of mscs	Type of study	Outcomes
Yao et al. ²⁰⁷	2012	BM-MSCs	Alkali burns rat model	Subconjunctival injection of BM-MSCs significantly accelerates corneal wound healing, attenuates inflammation and reduces CNV in alkaline-burned corneas.
Zhou et al. ²¹⁵	2022	Human UC-MSC-exo	Prospective clinical trial in human	UC-MSC-exo application in GVHD-associated dry eye resulted in reduced fluorescein scores, prolonged tear-film breakup time, increased tear secretion, and lower OSDI scores.
Martínez-Carrasco et al. ¹²²	2019	Human MSCs	oGVHD mouse model	hMSCs subconjunctival injection is effective in reducing corneal inflammation and squamous metaplasia.
Sánchez-Abarca et al. ¹⁵⁶	2015	GFP(+)-transduced human BM-MSCs	oGVHD mouse model	BM-MSCs distribute across the whole mouse cornea after subconjunctival injection and acquire in vivo features characteristic of epithelium, stroma, and endothelium.
Weng et al. ²⁰⁴	2012	Human BM-MSCs	Clinical trial in human	Intravenous BM-MSCs improved dry eye scores, ocular surface disease index scores, Schirmer test results and increased Tregs.

Adipose-Derived Mesenchymal Stem Cell-Derived Exosomes (ADSC-Exos), Antigen-Presenting Cell (APC), Benzalkonium Chloride (BAC), Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs), Cultivated Limbal Epithelial Transplantation (CLET), Dendritic Cells (DCs), Draining Lymph Nodes (DLNs), Dry Eye Disease (DED), EGFP-Expressing- Mesenchymal Stem Cells (eGFP-MSC), EGFP-Labeled Limbal Mesenchymal Stem Cells (L-MSCs-EGFP), Experimental Sjögrens Syndrome (ESS), Graft Versus Host Disease (GVHD), Human Adipose Tissue-Derived Mesenchymal Stem Cells (hAT-MSCs), Human Umbilical Cord-Derived Mscs (hUC-MSCs), Human Umbilical Cord-Derived MSC-Derived Extracellular Vesicles (hUC-MSC-seVs), Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells (iPSC-MSCs), Intravenous (IV), Lacrimal Glands (LGs), Limbal Epithelial Stem Cells (LSCs), Limbal Stem Cell Deficiency (LSCD), Mesenchymal Stem Cell-Derived Exosomes (MSC-Exos), Mesenchymal Stromal Cells-Derived Extracellular Vesicles (MSC-EVs), Mesenchymal Stem Cells Extract

T cells infiltration and decreased pro-inflammatory markers such as interleukin-2 and IFN- γ both in intraorbital glands and at the ocular surface¹⁰⁸. Ultimately, studies have demonstrated that the application of MSC-conditioned media in dry eye therapy could amplify treatment efficacy by attenuating inflammatory and apoptotic mechanisms, while also promoting tear production and stimulating the growth of corneal epithelial cells. This underscores the promise of harnessing the MSC secretome.²¹

3.1.2. Corneal transplantation

Corneal transplantation one of the most performed solid organ transplantation⁶⁴ with the highest successful rate^{134,180}. Although corneal allografts exhibit elevated rates of survival owing to immune privilege, the predominant reason for graft failure remains the threat of immune rejection.^{207,216} In most uncomplicated cases, this procedure necessitates only topical immunosuppression to ensure graft survival, obviating the necessity for histocompatibility matching in routine keratoplasty⁵⁵. This phenomenon can be attributed to the concept of "immune privilege"^{14,124,134,181}, which contributes significantly to its high success rate in humans and experimental animals^{134,180}. When a corneal transplant involves low-risk conditions, such as nonvascularized and uninfamed host beds, it yields a survival of the graft of more than 90 %¹⁴⁷; however, in cases involving patients who underwent multiple surgery due to previously failed transplantation or in case of vascularized and inflamed host beds, the success rate diminishes considerably, resulting in more than 50 % of grafts failing^{39,59}.

Given their ability to modulate the immune response, MSCs show promise for use in corneal allograft transplantation. In a model of high-risk corneal transplantation in rats, subconjunctival MSCs derived exosomes subconjunctivally injected significantly prolonged graft survival time, inhibiting infiltration of effector T cells, and reducing levels of IFN- γ and CXCL11, involved in attracting immune cells such as T cells and dendritic cells to sites of inflammation⁹². Similarly, subconjunctival injections of MSCs derived from bone-marrow in rats corneal allograft notably extended the survival of the grafts and ameliorated clinical outcomes, decreasing opacity, edema, neovascularization, Th1 cell and macrophage activation, along with an increase in Tregs function¹¹⁷. In an analogous corneal allograft rejection rat model, injection of MSCs after corneal transplantation significantly extended graft survival and suppress the adaptive-immune response in the allograft⁹¹. Allogeneic MSCs intravenously injected in rats pre-sensitized to donor antigens extended rejection-free graft survival and significantly promoted Treg

differentiation and function in the draining lymph nodes¹¹⁶. Additionally, intravenous infusion of human derived MSCs in a murine model of allogeneic corneal transplantation inhibited maturation and migration of CCR7 + antigen presenting cells from the cervical draining lymph nodes to the cornea⁷⁹. In another study, administration of syngeneic MSCs in corneal allograft recipients following surgery reduced antigen presenting cells in both the corneal graft and lymph nodes, leading to increased allograft survival rate¹⁴⁰. Furthermore, utilizing a rat corneal transplant model, it was demonstrated that treatment with allogeneic bone marrow derived MSCs notably enhanced the survival duration of corneal allografts, reduced the infiltration of natural killer cells in the corneas and, concurrently, significantly promoted Treg function in the recipients, showing low immunogenicity and potent immunoregulatory function of these cells¹⁸⁹. Interestingly, intravenous injection of human MSCs suppressed inflammation induced in the early phase following surgery and reduced activation of antigen presenting cells, resulting in prolonged allograft survival¹³⁸. Additionally, TGF- β -1 priming of MSCs cells has been shown to significantly improve corneal graft survival, indicating their superior therapeutic efficacy in modulating immune rejection of corneal allografts¹¹⁹. Moreover, the paracrine activity of MSCs holds considerable potential in corneal transplantation by shaping the local environment and regulating the immune response. MSCs secrete numerous factors like platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and transforming growth factor beta 1 (TGF- β -1)^{20,128,141}. Interestingly, it is notable how these factors, which can promote neovascularization in ischemic conditions such as myocardial infarction^{184,204}, contribute to suppressing neoangiogenesis and rejection in corneal transplants⁵⁷. These findings emphasize the context-dependent efficacy of MSCs therapy and their capacity to mitigate inflammation and immune activation².

3.1.3. Limbal stem cell deficiency

Limbal stem cells (LSCs) possess significant proliferative capabilities, enabling effective regeneration and restoration of the cornea.^{107,109,190} These LSCs are primarily located within specialized regions at the limbus, delineating a niche of stem cell⁴¹. Within the highly vascularized and innervated limbal microenvironment, LSCs closely interact with a variety of cells (melanocytes, stromal cells, extracellular matrix)^{49,160}. These interactions confer dual roles to the limbus: acting as a barrier between the corneal and conjunctival epithelium, and actively replenishing corneal epithelial cells³⁶. Both functions are critical for

maintaining ocular surface homeostasis, contributing to corneal integrity and transparency, therefore preserving vision under physiological conditions.

Limbal stem cell deficiency (LSCD) is a complex pathology with a multifaceted origin, resulting in the partial or complete loss of the cornea's regenerative capacity¹¹³. Pathologies affecting LSCs or their supportive niche can precipitate LSCD, and these conditions may be congenital, traumatic, or acquired (including chemical or thermal ocular injuries, surgical trauma, use of contact lenses, radiation therapy), autoimmune (such as Stevens-Johnson syndrome, mucous membrane pemphigoid, Sjögren syndrome, vernal keratoconjunctivitis, graft-versus-host disease), or idiopathic⁹⁷. While LSCD can arise from a broad spectrum of primary and secondary causes, it is most often associated with severe chemical or thermal burns¹⁹³. Stem cell loss in the limbal region, resulting from significant injury, leads to permanent defects in the corneal epithelium and vision impairment due to conjunctivalization of the cornea¹⁶⁴.

Despite the array of surgical treatments, a reliable and effective method for managing severe LSCD, especially in bilateral cases, remains elusive⁴⁰. The use of autologous limbal cell transplantation has gained broad acceptance as a therapeutic strategy for treating unilateral limbal stem cell loss¹⁰⁰. Nevertheless, in instances of bilateral damage, allogeneic limbal cell transplantation is recommended⁴⁵, albeit with a notable risk of rejection and the need for extended systemic immunosuppressive therapy³². Consequently, MSCs have garnered attention as a potential treatment option with reduced or minimal immunogenic potential.

Intrastromal injection of MSCs derived from human bone marrow in a mouse model of corneal epithelial and limbal injury, improved wound healing, reduced neovascularization, and opacity¹⁷⁵. In a mouse model of chemical injury to the cornea, investigators demonstrated that Pax6 induced bone marrow-derived MSCs can adhere to and regenerate damaged corneas by forming stratified corneal epithelium⁶⁶. Another study demonstrated that EGFP labeled limbal MSCs, when seeded onto decellularized human amniotic membrane and transplanted into rabbits with LSCD, resulted in decreased limbal vascularization, neoangiogenesis, infiltration of inflammatory cells and increased epithelialization, despite the low survival of labeled cells in the host tissue¹⁰¹. In an alkali burn rabbit model, researchers demonstrated that subconjunctivally injected bone marrow-derived MSCs led to a significant reduction in the severity of LSCD, evidenced by smaller epithelial cell defects, less fluorescein staining, diminished corneal neovascularization, and a lowered goblet cell density in the cornea¹¹⁰. In a murine model of corneal injury, intra injection of induced pluripotent stem cell-derived MSCs or bone marrow-derived MSCs resulted in a significant decrease in corneal opacity and swelling, along with a notable reduction in inflammatory infiltration and a decrease in levels of proinflammatory cytokines, including TNF- α , interleukin-1 β , and interleukin-6²⁰⁸. Additionally, MSCs derived from human adipose tissue, when transplanted onto the ocular surface of rabbits with partial and total LSCD models, migrated to inflamed tissues and demonstrated safety and efficacy in reducing inflammation, corneal neovascularization, and opacity⁶⁵. In an alkali-injured rabbit model, bone marrow-derived MSCs and tissue-specific LSCs exhibited similar therapeutic effects, accelerating re-epithelialization, and decreasing neovascularization and local inflammation⁸¹. Reports indicate that when MSCs are combined with a polysaccharide scaffold, there is an observed multiplicative effect⁸⁰. This is demonstrated by the increased expression of anti-inflammatory cytokines such as TGF- β , and antiangiogenic factors, such as TSP-1⁹⁹. Additionally, MSCs derived from adipose tissue have been linked to simultaneous decrease in pro-inflammatory cytokines such as TNF- α , chemotactic factors like MIP-1 α and MCP-1, and pro-angiogenic factors including VEGF and MMP-2. These findings present promising prospects for a novel therapeutic application of MSCs^{27,206}. In an in vivo mouse model of ocular injury, it has been demonstrated that MSCs possess the capability to restore corneal transparency by secreting elevated levels of

HGF, consequently inhibiting activation of myofibroblasts. Intriguingly, this study also revealed that HGF alone could restore corneal transparency, supporting the rationale for utilizing specific factors secreted by MSCs in the treatment of ocular diseases¹²⁹. In humans, a sub-analysis of clinical trials involving patients suffering from LSCD demonstrated that MSCs transplantation induces similar structural changes in the limbal stem cell niche, including the presence of transition zones and palisades of Vogt, comparable to those observed with the cultivated limbal epithelial transplantation (CLET) technique.¹⁴³ A randomized and double-masked study demonstrated that MSCs transplantation was as safe and effective as CLET for patients with total and/or severe LSCD²⁴.

3.1.4. Ocular graft-versus-host disease

Ocular graft-versus-host disease (oGVHD) represents a major complication associated with allogeneic hematopoietic stem cell transplantation (HSCT), contributing to the elevated risk of non-relapse-related morbidity and mortality following HSCT¹⁷⁰. Graft-versus-host disease is characterized by a dysregulation of the immune response, particularly involving T cells from the donor that target the recipient's tissues^{167,173}.

Acute GVHD is an inflammatory condition with an incidence rate ranging from 30 % to 50 %²¹¹. It predominantly affects three target organs: the integumentary system, the gastrointestinal epithelium, and the liver and bile ducts, occasionally manifesting in the eyes and oral mucosa¹⁶⁷. On the other hand, chronic GVHD, with an incidence ranging from 10 % to 70 %, is the most prevalent persistent complication in allo-HSCT patients⁸. It can impact various organ systems, including the eyes, skin, oral mucosa, gastrointestinal tract, hepatobiliary system, lungs, genitalia, and joints⁸⁹. oGVHD develops in more than half of patients post allo-HSCT and in the majority of patients with systemic GVHD^{88,166}. oGVHD manifests with lacrimal glands, eyelids, and ocular surface involvement, causing inflammation and fibrosis. These alterations yield symptoms such as dry, painful eyes and signs of dry eye, and in severe cases, cicatricial conjunctivitis, potentially leading to significant visual impairment and decreased patient quality of life¹⁵².

Both acute and chronic GVHD are immune-mediated diseases involving various immune cells, including antigen presenting cells, B cells, and T effector cells. T cells (CD4 + and CD8 +) play a crucial role in the pathophysiology of GVHD, as both acute and chronic GVHD are driven by donor effector T-cell-mediated immune responses against host antigens, with regulation by Tregs^{15,34}. This T cell response is influenced by differences in host and donor antigen expression, including mismatched human and non-human leukocyte antigens polymorphisms¹²⁶.

The primary objective of treating oGVHD focuses is to safeguard the ocular surface, enhance the quantity and quality of the tear film, while also reducing inflammation through topical treatments. In cases where local interventions fail to sufficiently manage inflammation and alleviate symptoms, systemic immunosuppression becomes necessary^{25,89}. In this setting of disrupted immune balance, MSCs known for their vast differentiation capabilities and immunosuppressive properties emerge as a promising new treatment option for oGVHD. In a mouse model of GVHD, subconjunctival injection of human MSCs prevented T lymphocyte infiltration, reduced tear osmolality and TNF- α expression and inhibited corneal keratinization¹²¹. Subconjunctival injection of GFP (+)-transduced human bone marrow derived MSCs into a GVHD mouse model showed that these cells migrated and differentiated into corneal tissue with morphological features resembling epithelial, stromal, and endothelial cells¹⁵⁵. In a prospective clinical trial, topical administration of human umbilical cord MSCs exosomes in patients suffering from refractory oGVHD-associated DED resulted in reduced corneal fluorescein staining, prolonged tear-film breakup time, increased tear secretion, and decreased symptoms²¹⁴. Moreover, intravenous administration of bone marrow-derived MSCs in patients with refractory corneal epitheliopathy secondary to oGVHD demonstrated that this

treatment improved corneal fluorescein staining scores, symptoms scores, Schirmer test results, promoted immunosuppressive Treg function and suppression of pro-inflammatory Th1 cytokines (interleukin-2 and interferon- γ)²⁰³.

4. Limitations and future directions

While recently published and ongoing clinical trials are designed to elucidate the safety and efficacy of optimal MSCs route of administration to the ocular surface, there remains a critical need to deepen our understanding of the mechanisms underlying their interactions with the ocular environment¹⁷⁴. Administering MSCs through subconjunctival routes exhibits greater therapeutic effectiveness in treating inflammatory corneal diseases compared to topical or systemic administration¹⁶⁷.

While our review primarily delves into the immunoregulatory functions of MSCs in immune-mediated ocular surface diseases, we recognize the broader implications of MSCs in wound healing and regenerative capacities, especially pertinent in conditions like limbal stem cell LSCD, ocular surface injuries, DED, and oGVHD. These conditions often predispose patients to significant healing defects such as epithelial defects and ulcers¹⁹², where MSCs have shown promise in promoting tissue repair and regeneration⁷. Therefore, while emphasizing their immunomodulatory roles, it is crucial to acknowledge MSCs' multifaceted potential in addressing the complex challenges of ocular surface diseases through their regenerative properties. Interestingly, ongoing clinical trials (NCT04626583, NCT05705024) are experimenting the application of MSCs in the setting of non-healing corneal diseases. This underscores the importance of optimizing local administration, as it holds the most promise for translational applications. By comprehensively studying how MSCs communicate with their surroundings, we can refine existing protocols and develop innovative strategies that ensure long-term effectiveness in treating immune-mediated diseases.

We have synthesized current literature on the immunomodulatory properties of MSCs, particularly focusing on their paracrine secretion as a mechanism to modulate the immune environment in immune-mediated diseases. We underscore the profound immunosuppressive capacity of MSCs, which is predominantly mediated through their secretion of soluble factors, but also supported by direct cell-cell interactions. This paracrine activity includes the release of cytokines, growth factors, and extracellular vesicles that collectively dampen inflammatory responses and promote tissue repair. We believe that harnessing the immunomodulatory potential of MSCs holds significant promise for therapeutic interventions in various immune-mediated disorders. This perspective not only consolidates existing knowledge but also emphasizes the critical role of MSC-derived paracrine signaling in shaping immune responses and mitigating pathological processes in immune-related conditions.

Future research endeavors should be directed towards a comprehensive investigation of paracrine signaling mechanisms to ensure the long-term viability and effectiveness of MSC-based therapies. This deeper insight will not only enhance the scalability and reproducibility of MSC-based therapies but also broaden their application across a spectrum of ocular conditions. Therefore, future research should prioritize investigating the intricate interplay between MSCs and the ocular microenvironment to unlock their full therapeutic potential and facilitate their integration into standard clinical practice.

5. Conclusion

We have explored the versatile capabilities of MSCs in treating ocular surface diseases, highlighting their significant role in promoting corneal healing through the regulation of immune responses, positively impacting the clinical outcomes of patients suffering from a range of ocular surface conditions. As the body of research in this area expands, the potential of MSCs in developing new therapeutic approaches in

ophthalmology becomes increasingly promising.

CRediT authorship contribution statement

Sayan Basu: Writing – review & editing, Visualization, Validation, Methodology. **Sunil Chauhan:** Writing – review & editing, Visualization, Validation, Supervision. **Reza Dana:** Writing – review & editing, Supervision, Resources, Methodology. **Antonio Di Zazzo:** Writing – review & editing, Visualization, Validation, Supervision, Resources, Project administration, Methodology, Investigation, Conceptualization. **Tomas Blanco:** Writing – review & editing, Supervision, Project administration. **Thomas Dohlman:** Writing – review & editing, Visualization, Project administration, Methodology, Investigation. **Marco Coassin:** Writing – review & editing, Validation, Supervision, Project administration. **Pier Luigi Surico:** Writing – review & editing, Writing – original draft, Software, Methodology, Investigation, Conceptualization. **Vincenzo Barone:** Writing – review & editing, Writing – original draft, Software. **Rohan Bir Singh:** Writing – original draft, Visualization, Software, Resources, Methodology.

Declaration of Competing Interest

The authors have no conflicts of interest to disclose.

References

1. Abdelfattah NS, Amgad M, Zayed AA, Hussein H, El-Baky NA. Molecular underpinnings of corneal angiogenesis: advances over the past decade. cited 2024 Jan 7];9(5):768–79. *Int J Ophthalmol [Internet]*. 2016. <https://doi.org/10.18240/IJO.2016.05.24>
2. Alió del Barrio JL, De la Mata A, De Miguel MP, et al. Corneal regeneration using adipose-derived mesenchymal stem cells. cited 2024 Jan 8]; *Cells [Internet]*. 2022; 11(16). <https://doi.org/10.3390/CELLS11162549>.
3. Aluri HS, Samizadeh M, Edman MC, et al. Delivery of bone marrow-derived mesenchymal stem cells improves tear production in a mouse model of Sjögren's Syndrome. cited 2024 Jan 8]; *Stem Cells Int*. 2017;2017. <https://doi.org/10.1155/2017/3134543>.
4. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. cited 2024 Jan 7]; *Nat [Internet]*. 2006;443(7114):993–997. <https://doi.org/10.1038/NATURE05249>.
5. Amin S, Massoumi H, Tewari D, et al. Cell type-specific extracellular vesicles and their impact on health and disease. cited 2024 Jul 3]; *Int J Mol Sci [Internet]*. 2024; 25(5). <https://doi.org/10.3390/IJMS25052730>.
6. Amouzegar A, Chauhan SK. Effector and regulatory T cell trafficking in corneal allograft rejection. cited 2024 Mar 22]; *Mediat Inflamm [Internet]*. 2017;2017. <https://doi.org/10.1155/2017/8670280>.
7. An S, Anwar K, Ashraf M, et al. Wound-healing effects of mesenchymal stromal cell secretome in the cornea and the role of exosomes. cited 2024 Jul 3]; *Pharm [Internet]*. 2023;15(5). <https://doi.org/10.3390/PHARMACEUTICS15051486>.
8. Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the center for international blood and marrow transplant research. cited 2024 Jan 9]; *Biol Blood Marrow Transpl [Internet]*. 2015;21(2):266–274. <https://doi.org/10.1016/J.BBMT.2014.10.021>.
9. Argüeso P. Galectins as regulators of corneal inflammation. cited 2024 Jan 7]; *Curr Opin Physiol [Internet]*. 2021;19:17–21. <https://doi.org/10.1016/J.COPHYS.2020.08.021>.
10. Auriemma M, Brzoska T, Klenner L, et al. α -MSH-stimulated tolerogenic dendritic cells induce functional regulatory T cells and ameliorate ongoing skin inflammation. cited 2024 Jan 7]; *J Invest Dermatol [Internet]*. 2012;132(7): 1814–1824. <https://doi.org/10.1038/JID.2012.59>.
11. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. cited 2024 Jan 7]; *Annu Rev Immunol [Internet]*. 2000;18:767–811. <https://doi.org/10.1146/ANNUREV.IMMUNOL.18.1.767>.
12. Barabino S, Chen Y, Chauhan S, Dana R. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. cited 2024 Jan 7]; *Prog Retin Eye Res [Internet]*. 2012;31(3):271–285. <https://doi.org/10.1016/J.PRETEYERES.2012.02.003>.
13. Barbosa FL, Xiao Y, Bian F, et al. Goblet cells contribute to ocular surface immune tolerance-implications for dry eye disease. cited 2024 Jan 8]; *Int J Mol Sci [Internet]*. 2017;18(5). <https://doi.org/10.3390/IJMS18050978>.
14. Barker CF, Billingham RE. Immunologically privileged sites [cited 2024 Jan 8];25 (C). *Adv Immunol [Internet]*. 1977;1–54. [https://doi.org/10.1016/S0065-2776\(08\)60930-X](https://doi.org/10.1016/S0065-2776(08)60930-X).
15. Bastian D, Wu Y, Betts BC, Yu XZ. The IL-12 cytokine and receptor family in graft-vs.-host disease. cited 2024 Jan 9]; *Front Immunol [Internet]*. 2019;10(MAY). <https://doi.org/10.3389/FIMMU.2019.00988>.

16. Basu S, Hertsberg AJ, Funderburgh ML, et al. Human limbal biopsy-derived stromal stem cells prevent corneal scarring. cited 2024 Jul 3; *Sci Transl Med [Internet]*. 2014;6(266). <https://doi.org/10.1126/SCITRANSLMED.3009644>.
17. Beeravolu N, McKee C, Alamri A, et al. Isolation and characterization of mesenchymal stromal cells from human umbilical cord and fetal placenta. cited 2024 Jan 8; *J Vis Exp [Internet]*. 2017;(122). <https://doi.org/10.3791/55224>.
18. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. cited 2024 Jan 8; *Nat Rev Cancer [Internet]*. 2011 Apr;11(4):268–277. <https://doi.org/10.1038/NRC3034>.
19. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. cited 2024 Jan 7; *Nat [Internet]*. 2006;441(7090):235–238. <https://doi.org/10.1038/NATURE04753>.
20. Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. cited 2024 Jan 8; *J Intern Med [Internet]*. 2007;262(5):509–525. <https://doi.org/10.1111/J.1365-2796.2007.01844.X>.
21. Bouche Djatche WH, Zhu H, Ma W, et al. Potential of mesenchymal stem cell-derived conditioned medium/secretome as a therapeutic option for ocular diseases. cited 2024 Jan 8; *Regen Med [Internet]*. 2023;18(10):795–807. <https://doi.org/10.2217/RME-2023-0089>.
22. Brain SD, Williams TJ. Interactions between the tachykinins and calcitonin gene-related peptide lead to the modulation of oedema formation and blood flow in rat skin. cited 2024 Jan 7; *Br J Pharm [Internet]*. 1989;97(1):77–82. <https://doi.org/10.1111/J.1476-5381.1989.TB11926.X>.
23. Brown C, McKee C, Bakshi S, et al. Mesenchymal stem cells: cell therapy and regeneration potential. cited 2024 Jan 8; *J Tissue Eng Regen Med [Internet]*. 2019;13(9):1738–1755. <https://doi.org/10.1002/TERM.2914>.
24. Calonge M, Pérez I, Galindo S, et al. A proof-of-concept clinical trial using mesenchymal stem cells for the treatment of corneal epithelial stem cell deficiency. cited 2024 Jan 9; *Transl Res [Internet]*. 2019;206:18–40. <https://doi.org/10.1016/J.TRLS.2018.11.003>.
25. Carreno-Galeano JT, Dohlman TH, Kim S, Yin J, Dana R. A review of ocular graft-versus-host disease: pathophysiology, clinical presentation and management. cited 2024 Jan 9; *Ocul Immunol Inflamm [Internet]*. 2021;29(6):1190–1199. <https://doi.org/10.1080/09273948.2021.1939390>.
26. Carucci JA, Ignatius R, Wei Y, et al. Calcitonin gene-related peptide decreases expression of HLA-DR and CD86 by human dendritic cells and dampens dendritic cell-driven T cell-proliferative responses via the type I calcitonin gene-related peptide receptor. cited 2024 Jan 7; *J Immunol [Internet]*. 2000;164(7):3494–3499. <https://doi.org/10.4049/JIMMUNOL.164.7.3494>.
27. Cejkova J, Trosan P, Cejka C, et al. Suppression of alkali-induced oxidative injury in the cornea by mesenchymal stem cells growing on nanofiber scaffolds and transferred onto the damaged corneal surface. cited 2024 Jan 9; *Exp Eye Res [Internet]*. 2013;116:312–323. <https://doi.org/10.1016/J.EXER.2013.10.002>.
28. Chen Y, Chauhan SK, Saban DR, et al. Interferon- γ -secreting NK cells promote induction of dry eye disease. cited 2024 Jan 7; *J Leukoc Biol [Internet]*. 2011;89(6):965–972. <https://doi.org/10.1189/JLB.1110611>.
29. Chen Y, Wang S, Alemi H, Dohlman T, Dana R. Immune regulation of the ocular surface. cited 2024 Jan 7; *Exp Eye Res [Internet]*. 2022;218. <https://doi.org/10.1016/J.EXER.2022.109007>.
30. Chiu IM, Von Hehn CA, Woolf CJ. Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. cited 2024 Jan 7; *Nat Neurosci [Internet]*. 2012;15(8):1063–1067. <https://doi.org/10.1038/NN.3144>.
31. Cho WKJ, Mittal SK, Chauhan SK. Mesenchymal stromal cells suppress T-cell-mediated delayed-type hypersensitivity via ALCAM-CD6 interaction. cited 2024 Mar 24; *Stem Cells Transl Med [Internet]*. 2023;12(4):221–233. <https://doi.org/10.1093/STCLTM/STZAD012>.
32. Chotikavanich S, Poriswanish N, Luangaram A, et al. Genetic analysis of allogeneic donor cells after successful allo-limbal epithelial transplantation in simple and cultivated limbal epithelial transplantation procedures. cited 2024 Jan 9; *Sci Rep [Internet]*. 2023;13(1). <https://doi.org/10.1038/S41598-023-31261-Z>.
33. Christ B, Dollinger MM. The generation of hepatocytes from mesenchymal stem cells and engraftment into the liver. cited 2024 Jan 8; *Curr Opin Organ Transpl [Internet]*. 2011;16(1):69–75. <https://doi.org/10.1097/MOT.0B013E3283424F5B>.
34. Cohen JL, Boyer O. The role of CD4+CD25hi regulatory T cells in the physiopathology of graft-versus-host disease. cited 2024 Jan 9; *Curr Opin Immunol [Internet]*. 2006;18(5):580–585. <https://doi.org/10.1016/J.COI.2006.07.007>.
35. Costela-ruiz VJ, Melguizo-rodríguez L, Bellotti C, et al. Different sources of mesenchymal stem cells for tissue regeneration: a guide to identifying the most favorable one in orthopedics and dentistry applications. cited 2024 Jan 8; *Int J Mol Sci [Internet]*. 2022;23(11). <https://doi.org/10.3390/IJMS23116356>.
36. Cotsarelis G, Cheng SZ, Dong G, Sun TT, Lavker RM. Existence of slow-cycling limbal epithelial basal cells that can be preferentially stimulated to proliferate: implications on epithelial stem cells. cited 2024 Jan 8; *Cell [Internet]*. 1989;57(2):201–209. [https://doi.org/10.1016/0092-8674\(89\)90958-6](https://doi.org/10.1016/0092-8674(89)90958-6).
37. Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. cited 2024 Jan 8; *Ocul Surf [Internet]*. 2017;15(4):802–812. <https://doi.org/10.1016/J.JTOS.2017.08.003>.
38. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. cited 2024 Jan 8; *Ocul Surf [Internet]*. 2017;15(3):276–283. <https://doi.org/10.1016/J.JTOS.2017.05.008>.
39. Dana MR, Qian Y, Hamrah P. Twenty-five-year panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. cited 2024 Jan 8; *Cornea [Internet]*. 2000;19(5):625–643. <https://doi.org/10.1097/00003226-200009000-00008>.
40. Daniels JT, Dart JKG, Tuft SJ, Khaw PT. Corneal stem cells in review [cited 2024 Jan 9] *Wound Repair Regen [Internet]*. 2001;9(6):483–494. <https://doi.org/10.1046/J.1524-475X.2001.00483.X>.
41. Davanger M, Evensen A. Role of the pericorneal papillary structure in renewal of corneal epithelium. cited 2024 Jan 8; *Nat [Internet]*. 1971;229(5286):560–561. <https://doi.org/10.1038/229560A0>.
42. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. cited 2024 Jan 7; *Sci [Internet]*. 1999;285(5425):245–248. <https://doi.org/10.1126/SCIENCE.285.5425.245>.
43. Delgado M. Generating tolerogenic dendritic cells with neuropeptides. cited 2024 Jan 7; *Hum Immunol [Internet]*. 2009;70(5):300–307. <https://doi.org/10.1016/J.HUMIMM.2009.01.020>.
44. Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. cited 2024 Jan 7; *Amino Acids [Internet]*. 2013;45(1):25–39. <https://doi.org/10.1007/S00726-011-1184-8>.
45. Deng SX, Kruse F, Gomes JAP, et al. Global consensus on the management of limbal stem cell deficiency. cited 2024 Jan 9; *Cornea [Internet]*. 2020;39(10):1291–1302. <https://doi.org/10.1097/ICO.0000000000002358>.
46. Dietrich J, Ott L, Roth M, et al. MSC transplantation improves lacrimal gland regeneration after surgically induced dry eye disease in mice. cited 2024 Jan 8; *Sci Rep [Internet]*. 2019 Dec 1;9(1). <https://doi.org/10.1038/S41598-019-54840-5>.
47. Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. cited 2024 Jan 8; *Cell Transpl [Internet]*. 2011;20(1):5–14. <https://doi.org/10.3727/096368910X>.
48. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement [cited 2024 Jan 8] *Cytotherapy [Internet]*. 2006;8(4):315–317. <https://doi.org/10.1080/14653240600855905>.
49. Dziasko MA, Daniels JT. Anatomical features and cell-cell interactions in the human limbal epithelial stem cell niche. cited 2024 Jan 8; *Ocul Surf [Internet]*. 2016;14(3):322–330. <https://doi.org/10.1016/J.JTOS.2016.04.002>.
50. Ecoiffier T, El Annan J, Rashid S, Schaumberg D, Dana R. Modulation of integrin $\alpha 4 \beta 1$ (VLA-4) in dry eye disease. cited 2024 Jan 7; *Arch Ophthalmol [Internet]*. 2008;126(12):1695–1699. <https://doi.org/10.1001/ARCHOPHT.126.12.1695>.
51. El-Annan J, Goyal S, Zhang Q, et al. Regulation of T-cell chemotaxis by programmed death-ligand 1 (PD-L1) in dry eye-associated corneal inflammation. cited 2024 Jan 7; *Invest Ophthalmol Vis Sci [Internet]*. 2010;51(7):3418–3423. <https://doi.org/10.1167/IOVS.09-3684>.
52. Eleuteri S, Fierabracci A. Insights into the secretome of mesenchymal stem cells and its potential applications. cited 2024 Jan 8; *Int J Mol Sci [Internet]*. 2019;20(18). <https://doi.org/10.3390/IJMS20184597>.
53. Ellenberg D, Azar DT, Hallak JA, et al. Novel aspects of corneal angiogenic and lymphangiogenic privilege. cited 2024 Jan 7; *Prog Retin Eye Res [Internet]*. 2010 May;29(3):208–248. <https://doi.org/10.1016/J.PRETYERES.2010.01.002>.
54. Espana EM, Ti SE, Grueterich M, Touhami A, Tseng SCG. Corneal stromal changes following reconstruction by ex vivo expanded limbal epithelial cells in rabbits with total limbal stem cell deficiency. cited 2024 Jan 7; *Br J Ophthalmol [Internet]*. 2003;87(12):1509–1514. <https://doi.org/10.1136/BJO.87.12.1509>.
55. van Essen TH, Roelen DL, Williams KA, Jager MJ. Matching for Human Leukocyte Antigens (HLA) in corneal transplantation - to do or not to do. cited 2024 Jan 8; *Prog Retin Eye Res [Internet]*. 2015;46:84–110. <https://doi.org/10.1016/J.PRETYERES.2015.01.001>.
56. Ezzelarab M, Thomson AW. Tolerogenic dendritic cells and their role in transplantation. cited 2024 Jan 7; *Semin Immunol [Internet]*. 2011;23(4):252–263. <https://doi.org/10.1016/J.SMIM.2011.06.007>.
57. F L, SZ Z. Mesenchymal stem cells: Potential role in corneal wound repair and transplantation. cited 2024 Jul 3 *World J Stem Cells [Internet]*. 2014;6(3):296. <https://doi.org/10.4252/WJSC.V6I3.296>.
58. Ferrari G, Hajrasouliha AR, Sadrai Z, et al. Nerves and neovessels inhibit each other in the cornea. cited 2024 Jan 7; *Invest Ophthalmol Vis Sci [Internet]*. 2013;54(1):813–820. <https://doi.org/10.1167/IOVS.11-8379>.
59. Fink N, Stark W.J., Maguire M.G., et al. Effectiveness of histocompatibility matching in high-risk corneal transplantation: a summary of results from the Collaborative Corneal Transplantation Studies. *Cesk Oftalmol [Internet]*. 1994 [cited 2024 Jan 8];50(1):3–12. Available from: (<https://pubmed.ncbi.nlm.nih.gov/8137435/>).
60. Foulsham W, Marmalidou A, Amouzegar A, et al. Review: the function of regulatory T cells at the ocular surface. cited 2024 Jan 7; *Ocul Surf [Internet]*. 2017;15(4):652–659. <https://doi.org/10.1016/J.JTOS.2017.05.013>.
61. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. cited 2024 Jan 7; *J Exp Med [Internet]*. 2000;192(7):1027–1034. <https://doi.org/10.1084/JEM.192.7.1027>.
62. Fu X, Liu G, Halim A, et al. Mesenchymal stem cell migration and tissue repair. cited 2024 Jul 3; *Cells [Internet]*. 2019;8(8). <https://doi.org/10.3390/CELLS8080784>.
63. Funderburgh JL, Funderburgh ML, Du Y. Stem cells in the limbal stroma. cited 2024 Jul 3; *Ocul Surf [Internet]*. 2016;14(2):113–120. <https://doi.org/10.1016/J.JTOS.2015.12.006>.
64. Gain P, Jullienne R, He Z, et al. Global survey of corneal transplantation and eye banking. cited 2024 Jan 8; *JAMA Ophthalmol [Internet]*. 2016;134(2):167–173. <https://doi.org/10.1001/JAMAOPHTHALMOL.2015.4776>.
65. Galindo S, Herreras JM, López-Paniagua M, et al. Therapeutic effect of human adipose tissue-derived mesenchymal stem cells in experimental corneal failure due

- to limbal stem cell niche damage. cited 2024 Jan 9]; *Stem Cells [Internet]*. 2017;35(10):2160–2174. <https://doi.org/10.1002/STEM.2672>.
66. Gao J, Ding L, Xin Y, et al. Pax6-induced proliferation and differentiation of bone marrow mesenchymal stem cells into limbal epithelial stem cells. cited 2024 Jan 9]; *Stem Cells Dev [Internet]*. 2023;32(13–14):410–421. <https://doi.org/10.1089/SCD.2022.0249>.
 67. Giorgino R, Albano D, Fusco S, et al. Knee osteoarthritis: epidemiology, pathogenesis, and mesenchymal stem cells: what else is new? An update. cited 2024 Jan 8]; *Int J Mol Sci [Internet]*. 2023;24(7). <https://doi.org/10.3390/IJMS24076405>.
 68. Golchin A, Chatziparasidou A, Ranjbarvan P, Niknam Z, Ardeshtyrlajimi A. Embryonic stem cells in clinical trials: current overview of developments and challenges [cited 2024 Jan 8] *Adv Exp Med Biol [Internet]*. 2021;1312:19–37. https://doi.org/10.1007/5584_2020_592.
 69. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. cited 2024 Jan 7]; *Annu Rev Immunol [Internet]*. 1998;16:111–135. <https://doi.org/10.1146/ANNUREV.IMMUNOL.16.1.111>.
 70. Grueterich M, Espana EM, Tseng SCG. Ex vivo expansion of limbal epithelial stem cells: amniotic membrane serving as a stem cell niche. cited 2024 Jan 7]; *Surv Ophthalmol [Internet]*. 2003;48(6):631–646. <https://doi.org/10.1016/j.survophthal.2003.08.003>.
 71. Guillaumat-Prats R. The role of MSC in wound healing, scarring and regeneration. cited 2024 Jan 8]; *Cells [Internet]*. 2021;10(7). <https://doi.org/10.3390/CELLS10071729>.
 72. Guo R, Liang Q, He Y, et al. Mesenchymal stromal cells-derived extracellular vesicles regulate dendritic cell functions in dry eye disease. cited 2024 Jan 8]; *Cells [Internet]*. 2022;12(1). <https://doi.org/10.3390/CELLS12010033>.
 73. Guzmán M, Keitelman I, Sabbione F, et al. Mucosal tolerance disruption favors disease progression in an extraorbital lacrimal gland excision model of murine dry eye. cited 2024 Jan 8]; *Exp Eye Res [Internet]*. 2016;151:19–22. <https://doi.org/10.1016/j.exer.2016.07.004>.
 74. Hamrah P, Liu Y, Zhang Q, Dana MR. The corneal stroma is endowed with a significant number of resident dendritic cells. cited 2024 Jan 7]; *Invest Ophthalmol Vis Sci [Internet]*. 2003;44(2):581–589. <https://doi.org/10.1167/IOVS.02-0838>.
 75. Hamrah P, Liu Y, Zhang Q, Dana MR. Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. cited 2024 Jan 7]; *Arch Ophthalmol [Internet]*. 2003;121(8):1132–1140. <https://doi.org/10.1001/ARCHOPHT.121.8.1132>.
 76. Hamrah P, Zhang Q, Liu Y, Dana MR. Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. *Invest Ophthalmol Vis Sci [Internet]*. 2002 Mar [cited 2019 Jul 21];43(3):639–646. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11867578>.
 77. Harrell CR, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. cited 2024 Jan 8 *Cells [Internet]*. 2019;12(8). <https://doi.org/10.3390/CELLS1208121605>.
 78. Hattori T, Chauhan SK, Lee H, et al. Characterization of Langerin-expressing dendritic cell subsets in the normal cornea. cited 2024 Jan 7]; *Invest Ophthalmol Vis Sci [Internet]*. 2011;52(7):4598–4604. <https://doi.org/10.1167/IOVS.10-6741>.
 79. HJ L, JH K, AY K, et al. Intravenous infusion of mesenchymal stem/stromal cells decreased CCR7(+) antigen presenting cells in mice with corneal allotransplantation. cited 2024 Jan 8]; *Curr Eye Res [Internet]*. 2014;39(8). <https://doi.org/10.3109/02713683.2013.877489>.
 80. Holan V, Javorkova E. Mesenchymal stem cells, nanofiber scaffolds and ocular surface reconstruction [cited 2024 Jan 9 *Stem Cell Rev Rep [Internet]*. 2013;9(5):609–619. <https://doi.org/10.1007/S12015-013-9449-0>.
 81. Holan V, Trosan P, Cejka C, et al. A comparative study of the therapeutic potential of mesenchymal stem cells and limbal epithelial stem cells for ocular surface reconstruction. cited 2024 Jan 9]; *Stem Cells Transl Med [Internet]*. 2015;4(9):1052–1063. <https://doi.org/10.5966/SC.TM.2015-0039>.
 82. Holzmann B. Antiinflammatory activities of CGRP modulating innate immune responses in health and disease. cited 2024 Jan 7]; *Curr Protein Pept Sci [Internet]*. 2013;14(4):268–274. <https://doi.org/10.2174/13892037113149990046>.
 83. Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: the international society for cellular therapy position statement. *Cytotherapy*. 2005;7(5):393–395. <https://doi.org/10.1080/14653240500319234>.
 84. Huang SJ, Fu RH, Shyu WC, et al. Adipose-derived stem cells: isolation, characterization, and differentiation potential. cited 2024 Jan 8]; *Cell Transpl [Internet]*. 2013;22(4):701–709. <https://doi.org/10.3727/096368912X655127>.
 85. Huang Y, Wu Q, Tam PKH. Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications. cited 2024 Jul 3]; *Int J Mol Sci [Internet]*. 2022;23(17). <https://doi.org/10.3390/IJMS231710023>.
 86. Huldani H, Margiana R, Ahmad F, et al. Immunotherapy of inflammatory bowel disease (IBD) through mesenchymal stem cells. cited 2024 Jan 8]; *Int Immunopharmacol [Internet]*. 2022;107. <https://doi.org/10.1016/J.INTIMP.2022.108698>.
 87. Inomata T, Hua J, Di Zazzo A, Dana R. Impaired function of peripherally induced regulatory T cells in hosts at high risk of graft rejection. cited 2024 Jun 10]; *Sci Rep [Internet]*. 2016;6. <https://doi.org/10.1038/SREP39924>.
 88. Jacobs R, Tran U, Chen H, et al. Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. cited 2024 Jan 9]; *Bone Marrow Transpl [Internet]*. 2012;47(11):1470–1473. <https://doi.org/10.1038/BMT.2012.56>.
 89. Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. *Biol Blood Marrow Transplant*. 2015;21(3):389–401.e1. <https://doi.org/10.1016/j.bbmt.2014.12.001>.
 90. Jhanji V, Santra M, Riau AK, et al. Combined therapy using human corneal stromal stem cells and quiescent keratocytes to prevent corneal scarring after injury. cited 2024 Jul 3]; *Int J Mol Sci [Internet]*. 2022;23(13). <https://doi.org/10.3390/IJMS23136980>.
 91. Jia Z, Li F, Zeng X, Lv Y, Zhao S. The effects of local administration of mesenchymal stem cells on rat corneal allograft rejection. cited 2024 Jan 8]; *BMC Ophthalmol [Internet]*. 2018;18(1). <https://doi.org/10.1186/S12886-018-0802-6>.
 92. Jia Z, Lv Y, Zhang W, et al. Mesenchymal stem cell derived exosomes-based immunological signature in a rat model of corneal allograft rejection therapy. cited 2024 Jan 8]; *Front Biosci (Landmark Ed) [Internet]*. 2022;27(3). <https://doi.org/10.31083/J.FBL2703086>.
 93. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. cited 2024 Jan 8]; *Nat [Internet]*. 2002;418(6893):41–49. <https://doi.org/10.1038/NATURE00870>.
 94. Jin Y, Chauhan SK, Annan JEI, et al. A novel function for programmed death ligand-1 regulation of angiogenesis. cited 2024 Jan 7]; *Am J Pathol [Internet]*. 2011;178(4):1922–1929. <https://doi.org/10.1016/J.AJP.2010.12.027>.
 95. Kabelitz D, Medzhitov R. Innate immunity–cross-talk with adaptive immunity through pattern recognition receptors and cytokines. cited 2024 Jan 7]; *Curr Opin Immunol [Internet]*. 2007;19(1):1–3. <https://doi.org/10.1016/J.COI.2006.11.018>.
 96. Karakousis PC, John SK, Behling KC, et al. Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues. *Mol Vis [Internet]*. 2001;7:154–163 (Available from) (<https://pubmed.ncbi.nlm.nih.gov/11438800/>). cited 2024 Jan 7.
 97. Kate A, Basu S. A review of the diagnosis and treatment of limbal stem cell deficiency. cited 2024 Jan 8]; *Front Med*. 2022;9. <https://doi.org/10.3389/FMED.2022.836009>.
 98. Kaur S, Sohnen P, Swamynathan S, et al. Molecular nature of ocular surface barrier function, diseases that affect it, and its relevance for ocular drug delivery. cited 2024 Jan 7]; *Ocul Surf [Internet]*. 2023;30:3–13. <https://doi.org/10.1016/J.JTOS.2023.08.001>.
 99. Ke Y, Wu Y, Cui X, et al. Polysaccharide hydrogel combined with mesenchymal stem cells promotes the healing of corneal alkali burn in rats. cited 2024 Jan 9]; *PLOS One [Internet]*. 2015;10(3). <https://doi.org/10.1371/JOURNAL.PONE.0119725>.
 100. Khan-Farooqi H, Chodosh J. Autologous Limbal Stem Cell Transplantation: The Progression of Diagnosis and Treatment. cited 2024 Jan 9]; *Semin Ophthalmol [Internet]*. 2016 Mar 3;31(1–2):91–98. <https://doi.org/10.3109/08820538.2015.1114862>.
 101. Khorolskaya JI, Perepletchikova DA, Zhurenkov KE, et al. Corneal reconstruction with EGFP-labelled limbal mesenchymal stem cells in a rabbit model of limbal stem cell deficiency. cited 2024 Jan 9]; *Int J Mol Sci [Internet]*. 2023;24(6). <https://doi.org/10.3390/IJMS24065431>.
 102. Knickelbein JE, Watkins SC, Mcmenamin PG, Hendricks RL. Stratification of antigen-presenting cells within the normal cornea. cited 2024 Jan 7]; *Ophthalmol Eye Dis [Internet]*. 2009;1, OED.S2813. <https://doi.org/10.4137/OED.S2813>.
 103. Kodati S, Chauhan SK, Chen Y, et al. CCR7 is critical for the induction and maintenance of Th17 immunity in dry eye disease. cited 2024 Jan 7]; *Invest Ophthalmol Vis Sci [Internet]*. 2014;55(9):5871–5877. <https://doi.org/10.1167/IOVS.14-14481>.
 104. Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. cited 2024 Jan 8]; *Arthritis Res Ther [Internet]*. 2007;9(1). <https://doi.org/10.1186/AR2216>.
 105. Komneni VK, Nagineni CN, William A, Detrick B, Hooks JJ. IFN-gamma acts as anti-angiogenic cytokine in the human cornea by regulating the expression of VEGF-A and sVEGF-R1. cited 2024 Jan 7]; *Biochem Biophys Res Commun [Internet]*. 2008;374(3):479–484. <https://doi.org/10.1016/J.BBRC.2008.07.042>.
 106. Kroegel C, Glembycz MA, Barnes PJ. Characterization of eosinophil cell activation by peptides. Differential effects of substance P, melittin, and FMET-Leu-Phe. cited 2024 Jan 7]; *J Immunol [Internet]*. 1990;145(8):2581–2587. <https://doi.org/10.4049/jimmunol.145.8.2581>.
 107. Kruse FE. Stem cells and corneal epithelial regeneration [cited 2024 Jan Eye [Internet]. 1994;8(2):170–183. <https://doi.org/10.1038/EYE.1994.42>.
 108. Lee MJ, Ko AY, Ko JH, et al. Mesenchymal stem/stromal cells protect the ocular surface by suppressing inflammation in an experimental dry eye. cited 2024 Jan 8]; *Mol Ther [Internet]*. 2015;23(1):139–146. <https://doi.org/10.1038/MT.2014.159>.
 109. Lehrer MS, Sun TT, Lavker RM. Strategies of epithelial repair: modulation of stem cell and transit amplifying cell proliferation [cited 2024 Jan 8]; *J Cell Sci [Internet]*. 1998;111(19):2867–2875. <https://doi.org/10.1242/JCS.111.19.2867>.
 110. Li G, Zhang Y, Cai S, et al. Human limbal niche cells are a powerful regenerative source for the prevention of limbal stem cell deficiency in a rabbit model. cited 2024 Jan 9]; *Sci Rep [Internet]*. 2018;8(1). <https://doi.org/10.1038/S41598-018-24862-6>.
 111. Li H, Ghazanfari R, Zacharakis D, Lim HC, Scheding S. Isolation and characterization of primary bone marrow mesenchymal stromal cells. cited 2024 Jan 8]; *Ann N Y Acad Sci [Internet]*. 2016;1370(1):109–118. <https://doi.org/10.1111/NYAS.13102>.
 112. Li N, Gao Z, Zhao L, et al. MSC-derived small extracellular vesicles attenuate autoimmune dacryoadenitis by promoting M2 macrophage polarization and inducing tregs via miR-100-5p. cited 2024 Jan 8]; *Front Immunol [Internet]*. 2022;13. <https://doi.org/10.3389/FIMMU.2022.888949>.

113. Liang L, Sheha H, Li J, Tseng SCG. Limbal stem cell transplantation: new progresses and challenges. cited 2024 Jan 8]; *Eye (Lond) [Internet]*. 2009;23(10):1946–1953. <https://doi.org/10.1038/EYE.2008.379>.
114. Liu X, Li X, Zhu W, et al. Exosomes from mesenchymal stem cells overexpressing MIF enhance myocardial repair. cited 2024 Jan 8]; *J Cell Physiol [Internet]*. 2020; 235(11):8010–8022. <https://doi.org/10.1002/JCP.29456>.
115. Liu Z, Mikrani R, Zubair HM, et al. Systemic and local delivery of mesenchymal stem cells for heart renovation: challenges and innovations. cited 2024 Jan 8]; *Eur J Pharm [Internet]*. 2020;876. <https://doi.org/10.1016/J.EJPHAR.2020.173049>.
116. Lohan P, Murphy N, Treacy O, et al. Third-party allogeneic mesenchymal stromal cells prevent rejection in a pre-sensitized high-risk model of corneal transplantation. cited 2024 Jan 8]; *Front Immunol [Internet]*. 2018;9(NOV)). <https://doi.org/10.3389/FIMMU.2018.02666>.
117. Lu X, Chu C, Liu X, et al. High-throughput RNA-sequencing identifies mesenchymal stem cell-induced immunological signature in a rat model of corneal allograft rejection [cited 2024 Jan 8]; *PLoS One [Internet]*. 2019;14(9). <https://doi.org/10.1371/JOURNAL.PONE.0222515>.
118. Lu X, Li N, Zhao L, et al. Human umbilical cord mesenchymal stem cells alleviate ongoing autoimmune dacryoadenitis in rabbits via polarizing macrophages into an anti-inflammatory phenotype. cited 2024 Jan 8]; *Exp Eye Res [Internet]*. 2020;191. <https://doi.org/10.1016/J.EXER.2019.107905>.
119. Lynch K, Treacy O, Chen X, et al. TGF- β 1-licensed murine MSCs show superior therapeutic efficacy in modulating corneal allograft immune rejection in vivo. cited 2024 Jul 3]; *Mol Ther [Internet]*. 2020;28(9):2023–2043. <https://doi.org/10.1016/J.YMTHE.2020.05.023>.
120. Ma H, Lam PK, Siu WS, et al. Adipose tissue-derived mesenchymal stem cells (ADMSCs) and ADMSC-derived secretome expedited wound healing in a rodent model - a preliminary study. cited 2024 Jan 8]; *Clin Cosmet Invest Dermatol [Internet]*. 2021;14:753–764. <https://doi.org/10.2147/CCID.S298105>.
121. Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, et al. Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD. cited 2024 Jan 9]; *Ocul Surf [Internet]*. 2019;17(2):285–294. <https://doi.org/10.1016/J.JTOS.2019.01.001>.
122. Mawrie D, Bhattacharjee K, Sharma A, et al. Human orbital adipose tissue-derived mesenchymal stem cells possess neuroectodermal differentiation and repair ability. cited 2024 Jan 8]; *Cell Tissue Res [Internet]*. 2019;378(3):531–542. <https://doi.org/10.1007/S00441-019-03072-0>.
123. Mazzella M, Walker K, Cormier C, et al. Regulation of self-renewal and senescence in primitive mesenchymal stem cells by Wnt and TGF β signaling. cited 2024 Jan 8]; *Stem Cell Res Ther [Internet]*. 2023;14(1). <https://doi.org/10.1186/S13287-023-03533-Y>.
124. MEDAWAR PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. *Br J Exp Pathol [Internet]*. 1948 [cited 2024 Jan 8];29(1):58–69. Available from: (<https://pubmed.ncbi.nlm.nih.gov/18865105/>).
125. Meek KM, Knapp C. Corneal structure and transparency. cited 2024 Jul 3]; *Prog Retin Eye Res [Internet]*. 2015;49:1–16. <https://doi.org/10.1016/J.PRETYERES.2015.07.001>.
126. Milosevic S, Bachnick B, Karim K, et al. Identification of MHC II-restricted minor histocompatibility antigens after HLA-identical stem-cell transplantation. cited 2024 Jan 9]; *Transplant [Internet]*. 2010;90(9):1030–1035. <https://doi.org/10.1097/TP.0B013E3181F5470C>.
127. Mittal SK, Cho WK, Elbasiony E, et al. Mesenchymal stem cells augment regulatory T cell function via CD80-mediated interactions and promote allograft survival. cited 2024 Mar 24]; *Am J Transpl [Internet]*. 2022;22(6):1564–1577. <https://doi.org/10.1111/AJT.17001>.
128. Mittal SK, Foulsham W, Shukla S, et al. Mesenchymal stromal cells modulate corneal alloimmunity via secretion of hepatocyte growth factor. cited 2024 Mar 24]; *Stem Cells Transl Med [Internet]*. 2019;8(10):1030–1040. <https://doi.org/10.1002/SCTM.19-0004>.
129. Mittal SK, Omoto M, Amouzegar A, et al. Restoration of corneal transparency by mesenchymal stem cells. cited 2024 Jan 9]; *Stem Cell Rep [Internet]*. 2016;7(4): 583–590. <https://doi.org/10.1016/J.JSTEMCR.2016.09.001>.
130. Mochizuki M, Sugita S, Kamoi K. Immunological homeostasis of the eye. cited 2024 Jan 8]; *Prog Retin Eye Res [Internet]*. 2013;33(1):10–27. <https://doi.org/10.1016/J.PRETYERES.2012.10.002>.
131. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance [cited 2024 Jan 7] *Nat Rev Immunol [Internet]*. 2007;7(8):610–621. <https://doi.org/10.1038/NRI2132>.
132. Nahar S, Nakashima Y, Miyagi-Shiohira C, et al. Cytokines in adipose-derived mesenchymal stem cells promote the healing of liver disease. cited 2024 Jan 8]; *World J Stem Cells [Internet]*. 2018;10(11):146–159. <https://doi.org/10.4252/WJSC.V10.I11.146>.
133. Nakagawa T, Sasaki M, Kataoka-Sasaki Y, et al. Intravenous infusion of mesenchymal stem cells promotes the survival of random pattern flaps in rats. cited 2024 Jan 8]; *Plast Reconstr Surg [Internet]*. 2021;148(4):799–807. <https://doi.org/10.1097/PRS.00000000000008327>.
134. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. cited 2024 Jan 8]; *Nat Immunol [Internet]*. 2006;7(4):354–359. <https://doi.org/10.1038/NI1328>.
135. Nishida T, Inui M, Nomizu M. Peptide therapies for ocular surface disturbances based on fibronectin-integrin interactions. cited 2024 Jan 7]; *Prog Retin Eye Res [Internet]*. 2015;47:38–63. <https://doi.org/10.1016/J.PRETYERES.2015.01.004>.
136. Nolta JA, Galipeau J, Phinney DG. Improving mesenchymal stem/stromal cell potency and survival: proceedings from the International Society of Cell Therapy (ISCT) MSC preconference held in May 2018, Palais des Congrès de Montréal, Organized by the ISCT MSC Scientific Committee. *Cytotherapy*. 2020;22(3): 123–126. <https://doi.org/10.1016/j.jcyt.2020.01.004>.
137. O'Connor TM, O'Connell J, O'Brien DJ, et al. The role of substance P in inflammatory disease [cited 2024 Jan 7]; *J Cell Physiol [Internet]*. 2004;201(2): 167–180. <https://doi.org/10.1002/JCP.20061>.
138. Oh JY, Lee RH, Yu JM, et al. Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response. cited 2024 Jan 8]; *Mol Ther [Internet]*. 2012;20(11):2143–2152. <https://doi.org/10.1038/MT.2012.165>.
139. Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. cited 2024 Jan 7]; *Immun [Internet]*. 2013;38(3):414–423. <https://doi.org/10.1016/J.IMMUNI.2013.03.002>.
140. Omoto M, Katikireddy KR, Rezaadeh A, Dohlman TH, Chauhan SK. Mesenchymal stem cells home to inflamed ocular surface and suppress allosensitization in corneal transplantation. cited 2024 Jan 8]; *Invest Ophthalmol Vis Sci [Internet]*. 2014;55(10):6631–6638. <https://doi.org/10.1167/IOVS.14-15413>.
141. P. De Miguel M, Fuentes-Julian S, Blazquez-Martinez A, et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. cited 2024 Jan 8]; *Curr Mol Med [Internet]*. 2012;12(5):574–591. <https://doi.org/10.2174/156652412800619950>.
142. Patel SP, Dana R. Corneal lymphangiogenesis: implications in immunity. cited 2024 Jan 7]; *Semin Ophthalmol [Internet]*. 2009;24(3):135–138. <https://doi.org/10.1080/08820530902801320>.
143. Pérez I, Galindo S, López-Miguel A, et al. In vivo confocal microscopy in limbal stem cell deficiency after mesenchymal stem cell transplantation: a sub-analysis from a phase I-II clinical trial. cited 2024 Jan 9]; *Ophthalmol Ther [Internet]*. 2023; 12(6):3251–3262. <https://doi.org/10.1007/S40123-023-00809-7>.
144. Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. cited 2024 Jan 8]; *Ophthalmol [Internet]*. 2017; 124(11S):S4–S13. <https://doi.org/10.1016/J.OPHTHA.2017.07.010>.
145. Pittenger MF, Discher DE, Péault BM, et al. Mesenchymal stem cell perspective: cell biology to clinical progress. cited 2024 Jul 3]; *NPJ Regen Med [Internet]*. 2019;4(1). <https://doi.org/10.1038/S41536-019-0083-6>.
146. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. cited 2024 Jan 8]; *Sci [Internet]*. 1999 Apr 2;284(5411): 143–147. <https://doi.org/10.1126/SCIENCE.284.5411.143>.
147. Price FW, Whitson WE, Collins KS, Marks RG. Five-year corneal graft survival. A large, single-center patient cohort. cited 2024 Jan 8]; *Arch Ophthalmol [Internet]*. 1993;111(6):799–805. <https://doi.org/10.1001/ARCHOPHT.1993.01090060087029>.
148. Puri S, Kenyon BM, Hamrah P. Immunomodulatory role of neuropeptides in the cornea. cited 2024 Jan 7]; *Biomed [Internet]*. 2022;10(8). <https://doi.org/10.3390/BIOMEDICINES10081985>.
149. Qazi Y, Wong G, Monson B, Stringham J, Ambati BK. Corneal transparency: genesis, maintenance and dysfunction. cited 2024 Jan 7]; *Brain Res Bull [Internet]*. 2010;81(2–3):198–210. <https://doi.org/10.1016/J.BRAINRESBULL.2009.05.019>.
150. Rui K, Shen Z, Peng N, et al. Olfactory ecto-mesenchymal stem cell-derived exosomes ameliorate murine Sjögren's Syndrome via suppressing Th1 cell response. cited 2024 Jan 8]; *Rheumatol Immunol Res [Internet]*. 2022;3(4):198–207. <https://doi.org/10.2478/RIR-2022-0035>.
151. Sabatino F, Di Zazzo A, De Simone L, Bonini S. The intriguing role of neuropeptides at the ocular surface. cited 2024 Jan 7]; *Ocul Surf [Internet]*. 2017;15(1):2–14. <https://doi.org/10.1016/J.JTOS.2016.10.003>.
152. Saboo US, Amparo F, Abud TB, Schaumberg DA, Dana R. Vision-related quality of life in patients with ocular graft-versus-host disease. cited 2024 Jan 9]; *Ophthalmol [Internet]*. 2015;122(8):1669–1674. <https://doi.org/10.1016/J.OPHTHA.2015.04.011>.
153. Sahu A, Foulsham W, Amouzegar A, Mittal SK, Chauhan SK. The therapeutic application of mesenchymal stem cells at the ocular surface. cited 2024 Jan 7]; *Ocul Surf [Internet]*. 2019;17(2):198. <https://doi.org/10.1016/J.JTOS.2019.01.006>.
154. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. cited 2024 Jan 7]; *Cell [Internet]*. 2008;133(5):775–787. <https://doi.org/10.1016/J.CELL.2008.05.009>.
155. Sánchez-Abarca LI, Hernández-Galilea E, Lorenzo R, et al. Human bone marrow stromal cells differentiate into corneal tissue and prevent ocular graft-versus-host disease in mice. cited 2024 Jan 9]; *Cell Transpl [Internet]*. 2015;24(12):2423–2433. <https://doi.org/10.3727/096368915X687480>.
156. Sanjabi S, Oh SA, Li MO. Regulation of the immune response by TGF- β : from conception to autoimmunity and infection. cited 2024 Jan 7]; *Cold Spring Harb Perspect Biol [Internet]*. 2017;9(6). <https://doi.org/10.1101/CSHPERSPECT.A022236>.
157. Santos, Dos A, Balayan A, et al. Differentiation capacity of human mesenchymal stem cells into keratocyte lineage. cited 2024 Jul 3]; *Invest Ophthalmol Vis Sci [Internet]*. 2019;60(8):3013–3023. <https://doi.org/10.1167/IOVS.19-27008>.
158. Santra M, Geary ML, Rubin E, et al. Good manufacturing practice production of human corneal limbus-derived stromal stem cells and in vitro quality screening for therapeutic inhibition of corneal scarring. cited 2024 Jul 3]; *Stem Cell Res Ther [Internet]*. 2024;15(1). <https://doi.org/10.1186/S13287-023-03626-8>.
159. Saria A. Substance P in sensory nerve fibres contributes to the development of oedema in the rat hind paw after thermal injury. cited 2024 Jan 7]; *Br J Pharm [Internet]*. 1984;82(1):217–222. <https://doi.org/10.1111/J.1476-5381.1984.TB16461.X>.
160. Scadden DT. The stem-cell niche as an entity of action. cited 2024 Jan 8]; *Nat [Internet]*. 2006;441(7097):1075–1079. <https://doi.org/10.1038/NATURE04957>.

161. Sehrawat S, Reddy PBJ, Rajasagi N, et al. Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. cited 2024 Jan 7; *PLOS Pathog* [Internet]. 2010;6(5):1–16. <https://doi.org/10.1371/JOURNAL.PPAT.1000882>.
162. Sehrawat S, Suryawanshi A, Hirashima M, Rouse BT. Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators. cited 2024 Jan 7; *J Immunol* [Internet]. 2009;182(5):3191–3201. <https://doi.org/10.4049/JIMMUNOL.0803673>.
163. Shao C, Chen Y, Nakao T, et al. Local delivery of regulatory T cells promotes corneal allograft survival. cited 2024 Jul 3; *Transplant* [Internet]. 2019;103(1):182–190. <https://doi.org/10.1097/TP.0000000000002442>.
164. Shapiro M.S., Friend J., Thoft R.A. Corneal re-epithelialization from the conjunctiva. Invest Ophthalmol Vis Sci [Internet]. 1981 [cited 2024 Jan 9];21(1 Pt 1):135–142. Available from: (<https://pubmed.ncbi.nlm.nih.gov/7251297/>).
165. Shen L, Jin Y, Freeman GJ, Sharpe AH, Dana MR. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. cited 2024 Jan 7; *J Immunol* [Internet]. 2007;179(6):3672–3679. <https://doi.org/10.4049/JIMMUNOL.179.6.3672>.
166. Shikari H, Amparo F, Saboo U, Dana R. Onset of ocular graft-versus-host disease symptoms after allogeneic hematopoietic stem cell transplantation. cited 2024 Jan 9; *Cornea* [Internet]. 2015;34(3):243–247. <https://doi.org/10.1097/ICO.0000000000000340>.
167. Shikari H, Antin JH, Dana R. Ocular graft-versus-host disease: a review. cited 2019 Aug 20; *Surv Ophthalmol* [Internet]. 2013;58(3):233–251. <https://doi.org/10.1016/j.survophthal.2012.08.004>.
168. Shojati G, Khandaker I, Funderburgh ML, et al. Mesenchymal stem cells reduce corneal fibrosis and inflammation via extracellular vesicle-mediated delivery of miRNA. cited 2024 Jul 3; *Stem Cells Transl Med* [Internet]. 2019;8(11):1192–1201. <https://doi.org/10.1002/SCTM.18-0297>.
169. Shukla S, Mittal SK, Foulsham W, et al. Therapeutic efficacy of different routes of mesenchymal stem cell administration in corneal injury. cited 2024 Mar 24; *Ocul Surf* [Internet]. 2019;17(4):729–736. <https://doi.org/10.1016/J.JTOS.2019.07.005>.
170. Shulman HM, Cardona DM, Greenon JK, et al. NIH consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. cited 2024 Jan 9; *Biol Blood Marrow Transpl* [Internet]. 2015;21(4):589–603. <https://doi.org/10.1016/J.BBMT.2014.12.031>.
171. Singh RB, Blanco T, Mittal SK, et al. Pigment Epithelium-derived Factor secreted by corneal epithelial cells regulates dendritic cell maturation in dry eye disease. cited 2024 Jan 7; *Ocul Surf* [Internet]. 2020 Jul 1;18(3):460–469. <https://doi.org/10.1016/J.JTOS.2020.05.002>.
172. Singh RB, Blanco T, Mittal SK, et al. Pigment epithelium-derived factor enhances the suppressive phenotype of regulatory T cells in a murine model of dry eye disease. cited 2024 Jan 7; *Am J Pathol* [Internet]. 2021;191(4):720–729. <https://doi.org/10.1016/J.AJPATH.2021.01.003>.
173. Singh RB, Cho W, Liu C, et al. Immunopathological mechanisms and clinical manifestations of ocular graft-versus-host disease following hematopoietic stem cell transplantation. cited 2024 Jun 6 *Bone Marrow Transpl* [Internet]. 2024. <https://doi.org/10.1038/S41409-024-02321-3>.
174. Soleimani M, Masoumi A, Momenaei B, et al. Applications of mesenchymal stem cells in ocular surface diseases: sources and routes of delivery. cited 2024 Jul 3; *Expert Opin Biol Ther* [Internet]. 2023;23(6):509–525. <https://doi.org/10.1080/14712598.2023.2175605>.
175. Soleimani M, Mirshahi R, Cheraqpour K, et al. Intrastromal versus subconjunctival injection of mesenchymal stem/stromal cells for promoting corneal repair. cited 2024 Jan 9; *Ocul Surf* [Internet]. 2023;30:187–195. <https://doi.org/10.1016/J.JTOS.2023.09.008>.
176. Steinman L. Elaborate interactions between the immune and nervous systems. cited 2024 Jan 7; *Nat Immunol* [Internet]. 2004;5(6):575–581. <https://doi.org/10.1038/NI1078>.
177. Stern ME, Schaumburg CS, Siemasko KF, et al. Autoantibodies contribute to the immunopathogenesis of experimental dry eye disease. cited 2024 Jan 8; *Invest Ophthalmol Vis Sci* [Internet]. 2012;53(4):2062–2075. <https://doi.org/10.1167/IOVS.11-9299>.
178. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. cited 2024 Jan 8; *Arch Ophthalmol* [Internet]. 2012;130(1):90–100. <https://doi.org/10.1001/ARCHOPHTHALMOL.2011.364>.
179. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. cited 2024 Jan 7; *Curr Opin Immunol* [Internet]. 2007;19(3):281–286. <https://doi.org/10.1016/J.COI.2007.04.005>.
180. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. cited 2024 Jan 8 *Nat Rev Immunol* [Internet]. 2003;3(11):879–889. <https://doi.org/10.1038/NRI1224>.
181. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. cited 2024 Jan 8 *Nat Rev Immunol* [Internet]. 2003;3(11):879–889. <https://doi.org/10.1038/NRI1224>.
182. Su YF, Lin CS, Hung SC, Yang KY. Mesenchymal stem cell-conditioned medium induces neutrophil apoptosis associated with inhibition of the NF- κ B pathway in endotoxin-induced acute lung injury. cited 2024 Jan 8; *Int J Mol Sci* [Internet]. 2019;20(9). <https://doi.org/10.3390/IJMS20092208>.
183. Summer S, Rossmanith E, Pasztoerek M, et al. Mesenchymal stem cells support human vascular endothelial cells to form vascular sprouts in human platelet lysate-based matrices. cited 2024 Jan 8; *PLoS One* [Internet]. 2022;17(12). <https://doi.org/10.1371/JOURNAL.PONE.0278895>.
184. Sun J, Shen H, Shao L, et al. HIF-1 α overexpression in mesenchymal stem cell-derived exosomes mediates cardioprotection in myocardial infarction by enhanced angiogenesis. cited 2024 Jan 8; *Stem Cell Res Ther* [Internet]. 2020;11(1). <https://doi.org/10.1186/S13287-020-01881-7>.
185. Sun T, Liu S, Yang G, et al. Mesenchymal stem cell transplantation alleviates Sjögren's syndrome symptoms by modulating Tim-3 expression. cited 2024 Jan 8; *Int Immunopharmacol* [Internet]. 2022;111. <https://doi.org/10.1016/J.INTIMP.2022.109152>.
186. Surico PL, Scarabosio A, Miotti G, et al. Unlocking the versatile potential: adipose-derived mesenchymal stem cells in ocular surface reconstruction and oculoplastics. cited 2024 Mar 5; *World J Stem Cells* [Internet]. 2024;16(2):89–101. <https://doi.org/10.4252/WJSC.V16.I2.89>.
187. Tan Y, Ooi S, Wang L. Immunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: genetic and epigenetic perspectives. *Curr Stem Cell Res Ther* [Internet]. 2014;9(1):63–72. <https://doi.org/10.2174/1574888X113086660068>.
188. Tavakoli S, Ghaderi Jafarbeigloo HR, Shariati A, et al. Mesenchymal stromal cells; a new horizon in regenerative medicine. cited 2024 Jan 8; *J Cell Physiol* [Internet]. 2020 \235(12):9185–9210. <https://doi.org/10.1002/JCP.29803>.
189. Treacy O, O'Flynn L, Ryan AE, et al. Mesenchymal stem cell therapy promotes corneal allograft survival in rats by local and systemic immunomodulation. cited 2024 Jan 8; *Am J Transpl* [Internet]. 2014;14(9):2023–2036. <https://doi.org/10.1111/AJT.12828>.
190. Tseng SCG. Regulation and clinical implications of corneal epithelial stem cells. cited 2024 Jan 8; *Mol Biol Rep* [Internet]. 1996;23(1):47–58. <https://doi.org/10.1007/BF00357072>.
191. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. *Nat Rev Immunol* [Internet]. 2008;8(9):726–736. <https://doi.org/10.1038/NRI2395>.
192. Vaidyanathan U., Hopping G.C., Liu H.Y., et al. Persistent Corneal Epithelial Defects: A Review Article. Medical Hypothesis, Discovery and Innovation in Ophthalmology [Internet]. 2019 [cited 2024 Jul 3];8(3):163. Available from: /pmc/articles/PMC6778469/.
193. Vazirani J, Nair D, Shanbhag S, et al. Limbal stem cell deficiency-demography and underlying causes. cited 2024 Jan 9; *Am J Ophthalmol* [Internet]. 2018;188:99–103. <https://doi.org/10.1016/J.AJO.2018.01.020>.
194. Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. cited 2024 Jan 7; *Nat Rev Immunol* [Internet]. 2008;8(7):523–532. <https://doi.org/10.1038/NRI2343>.
195. Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: international society for cell & gene therapy (ISCT®) mesenchymal stromal cell committee position statement on nomenclature. cited 2024 Mar 24; *Cytotherapy* [Internet]. 2019;21(10):1019–1024. <https://doi.org/10.1016/J.JCYT.2019.08.002>.
196. Wan YY, Flavell RA. Yin-Yang" functions of transforming growth factor-beta and T regulatory cells in immune regulation.. cited 2024 Jan 7; *Immunol Rev* [Internet]. 2007;220(1):199–213. <https://doi.org/10.1111/J.1600-065X.2007.00565.X>.
197. Wang G, Li H, Long H, et al. Exosomes derived from mouse adipose-derived mesenchymal stem cells alleviate benzalkonium chloride-induced mouse dry eye model via inhibiting NLRP3 inflammasome. cited 2024 Jan 8; *Ophthalmic Res* [Internet]. 2022;65(1):40–51. <https://doi.org/10.1159/000519458>.
198. Wang L, Wang X, Chen Q, et al. MicroRNAs of extracellular vesicles derived from mesenchymal stromal cells alleviate inflammation in dry eye disease by targeting the IRAK1/TAB2/NF- κ B pathway. cited 2024 Jan 8; *Ocul Surf* [Internet]. 2023;28:131–140. <https://doi.org/10.1016/J.JTOS.2023.03.002>.
199. Wang S, Kahale F, Naderi A, et al. Therapeutic effects of stimulating the melanocortin pathway in regulating ocular inflammation and cell death. Vol 14, Page 169 [Internet] *Biomolecules* 2024. 2024;14(2):169. <https://doi.org/10.3390/BIOM14020169>.
200. Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. cited 2024 Jan 8; *Nat Immunol* [Internet]. 2014;15(11):1009–1016. <https://doi.org/10.1038/NI.3002>.
201. Wang Y, Pan J, Wang D, Liu J. The use of stem cells in neural regeneration: A review of current opinion. cited 2024 Jan 8; *Curr Stem Cell Res Ther* [Internet]. 2018;13(7):608–617. <https://doi.org/10.2174/1574888X13666180720100738>.
202. Wang Y, Wang X, Zou Z, et al. Conditioned medium from bone marrow mesenchymal stem cells relieves spinal cord injury through suppression of Gal-3/NLRP3 and M1 microglia/macrophage polarization. cited 2024 Jan 8; *Pathol Res Pr* [Internet]. 2023;243. <https://doi.org/10.1016/J.PRP.2023.154331>.
203. Weng J, He C, Lai P, et al. Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease. cited 2024 Jan 9; *Mol Ther* [Internet]. 2012;20(12):2347–2354. <https://doi.org/10.1038/MT.2012.208>.
204. Xiao Y, Zhang Y, Li Y, et al. Exosomes derived from mesenchymal stem cells pretreated with ischemic rat heart extracts promote angiogenesis via the delivery of DMBT1. cited 2024 Jan 8; *Cell Transpl* [Internet]. 2022;31. <https://doi.org/10.1177/09636897221102898>.
205. Yamagami S, Hamrah P, Miyamoto K, et al. CCR5 chemokine receptor mediates recruitment of MHC class II-positive Langerhans cells in the mouse corneal epithelium. cited 2024 Jan 7; *Invest Ophthalmol Vis Sci* [Internet]. 2005;46(4):1201–1207. <https://doi.org/10.1167/IOVS.04-0658>.
206. Yao L, Li Z, rong, Su W, ru, et al. Role of mesenchymal stem cells on cornea wound healing induced by acute alkali burn. cited 2024 Jan 9; *PLoS One* [Internet]. 2012 Feb 17;2(2). <https://doi.org/10.1371/JOURNAL.PONE.0030842>.
207. Yin J. Advances in corneal graft rejection. cited 2024 Jan 8; *Curr Opin Ophthalmol* [Internet]. 2021;32(4):331–337. <https://doi.org/10.1097/ICU.0000000000000767>.
208. Yun YI, Park SY, Lee HJ, et al. Comparison of the anti-inflammatory effects of induced pluripotent stem cell-derived and bone marrow-derived mesenchymal stromal cells in a murine model of corneal injury. cited 2024 Jan 9; *Cytotherapy* [Internet]. 2017;19(1):28–35. <https://doi.org/10.1016/J.JCYT.2016.10.007>.

209. Di Zazzo A, Gaudenzi D, Yin J, et al. Corneal angiogenic privilege and its failure. cited 2024 Jan 7]; *Exp Eye Res [Internet]*. 2021 Mar 1;204. <https://doi.org/10.1016/J.EXER.2021.108457>.
210. Di Zazzo A, Tahvildari M, Subbarayal B, et al. Proangiogenic function of T ntation. cited 2024 Jan 7]; *Transplant [Internet]*. 2017;101(4):778–785. <https://doi.org/10.1097/TP.0000000000001390>.
211. Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. cited 2024 Jan 9]; *N Engl J Med [Internet]*. 2017;377(22):2167–2179. <https://doi.org/10.1056/NEJMRA1609337>.
212. Zhang C, Xiao J, Fa L, et al. Advances in the applications of mesenchymal stem cell-conditioned medium in ocular diseases. cited 2024 Jan 8]; *Exp Eye Res [Internet]*. 2023;233. <https://doi.org/10.1016/J.EXER.2023.109560>.
213. Zhao H, Liao X, Kang Y. Tregs: where we are and what comes next?. cited 2024 Jan 7] *Front Immunol [Internet]*. 2017;8(NOV). <https://doi.org/10.3389/FIMMU.2017.01578>.
214. Zhou T, He C, Lai P, et al. miR-204-containing exosomes ameliorate GVHD-associated dry eye disease. cited 2024 Jan 9]; *Sci Adv [Internet]*. 2022;8(2). <https://doi.org/10.1126/SCIADV.ABJ9617>.
215. Zhou T, Yuan Z, Weng J, et al. Challenges and advances in clinical applications of mesenchymal stromal cells. cited 2024 Jan 8]; *J Hematol Oncol [Internet]*. 2021;14(1). <https://doi.org/10.1186/S13045-021-01037-X>.
216. Zhu J, Inomata T, Di Zazzo A, et al. Role of immune cell diversity and heterogeneity in corneal graft survival: a systematic review and meta-analysis. cited 2024 Jan 8]; *J Clin Med [Internet]*. 2021;10(20). <https://doi.org/10.3390/JCM10204667>.